[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1260
1. Konukoglu E, Wells WM, Novellas S, Ayache N, Kikinis R, Black PM, Pohl KM: MONITORING SLOWLY EVOLVING TUMORS. Proc IEEE Int Symp Biomed Imaging; 2008 May;2008:812-815

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MONITORING SLOWLY EVOLVING TUMORS.
  • Change detection is a critical task in the diagnosis of many slowly evolving pathologies.
  • We are specifically interested in meningiomas, which experts often find difficult to monitor as the tumor evolution can be obscured by image artifacts.
  • We test the method on synthetic data with known tumor growth as well as ten clinical data sets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):319-26 [18044584.001]
  • [Cites] Comput Med Imaging Graph. 2005 Jan;29(1):21-34 [15710538.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):163-79 [12045002.001]
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Oct;24(10):1334-46 [16229419.001]
  • [Cites] Clin Radiol. 2007 Jan;62(1):10-7 [17145258.001]
  • (PMID = 28593030.001).
  • [ISSN] 1945-7928
  • [Journal-full-title] Proceedings. IEEE International Symposium on Biomedical Imaging
  • [ISO-abbreviation] Proc IEEE Int Symp Biomed Imaging
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCRR NIH HHS / RR / P41 RR019703; United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; follow-up / time series analysis / tumor
  •  go-up   go-down


2. Lepère C, Rakotomalala S, Maindrault-Goebel F, Mitry E, Vaillant JN, Julie C, Otmezguine Y, Rougier P: [Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases]. Gastroenterol Clin Biol; 2007 Apr;31(4):445-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases].
  • [Transliterated title] Traitement conservateur des tumeurs endocrines peu différenciées du canal anal.
  • Undifferentiated neuroendocrine tumors are rare, and are characteristically aggressive with a poor prognosis.
  • Most patients have metastatic disease at diagnosis, and cannot undergo curative surgical treatment.
  • We report two cases of poorly differentiated neuroendocrine tumors localized in the anal canal and treated by chemotherapy and radiotherapy resulting in prolonged complete local remission and preventing extended surgical excision.
  • [MeSH-major] Anus Neoplasms / therapy. Brain Neoplasms / secondary. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Anal Canal / pathology. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Male. Radiotherapy Dosage. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483787.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Ortholan C, François E, Gérard JP: [Chemoradiotherapy and anal canal cancer]. Bull Cancer; 2005 Dec;92(12):1039-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiotherapy and anal canal cancer].
  • [Transliterated title] Chimioradiothérapie des cancers du canal anal.
  • Local control and sphincter preservation are the two challenges of anal canal cancer treatment.
  • These tumors are radio- and chemo-sensitive and treatment moved from surgical approach, with abdominoperineal resection, to definitive radiation therapy with or without concurrent chemotherapy.
  • Indications of chemoradiotherapy are locally advanced tumor T2 > or = 4 cm, T3-4 or N1-3 but the best modalities of combined treatment are still under debate.
  • This article is a review of past randomised trials, phases II and retrospective study on radiochemotherapy of anal canal carcinoma.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396750.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Pyrimidines; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Soumarová R, Homola L, Perková H, Czudek S, Skrovina M, Adamcík L: [The role of interstitial brachytherapy in multimodality management of solid tumors]. Rozhl Chir; 2007 Oct;86(10):533-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of interstitial brachytherapy in multimodality management of solid tumors].
  • Its prons include, in particular, a possibility to apply a dose, in addition to external radiotherapy, directly into the tumor region or its focus, which may improve treatment success rates in patients with localized tumors.
  • The commonest diagnoses, where interstitial brachytherapy is employed, include the following: breast carcinomas, soft tissue sarcomas, head and neck tumors, gynaecological tumors, penile and anal tumors and prostate tumors.
  • [MeSH-major] Brachytherapy. Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064791.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 54
  •  go-up   go-down


5. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller R, Nathan M, Coleman N: Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2855-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.
  • PURPOSE: Early detection of anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) by screening will improve clinical outcome.
  • Assessment of anal cytology samples using routine Papanicolaou testing suffers from shortcomings in sensitivity and/or specificity, suggesting that screening tests based on biomarkers may be of value.
  • EXPERIMENTAL DESIGN: We undertook an initial immunohistochemical study of 54 anal tissue samples and validated our findings using an independent prospective cohort study of 235 anal cytology samples from 144 subjects.
  • RESULTS: In the progression from normal anal epithelium through AIN to SCC, there was increasing expression of MCM2 and MCM5, including in the superficial epithelial third, the source of the majority of cells collected by anal swab.
  • By immunocytochemistry using a mixture of anti-MCM2 and anti-MCM5 antibodies, immunopositive cells were readily identified in anal cytology samples, even at low magnification.
  • CONCLUSIONS: MCMs are promising biomarkers for improving detection of AIN and SCC in anal cytology samples.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / / MC/ U105359878; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


6. Berton F, Gola G, Wilson SR: Perspective on the role of transrectal and transvaginal sonography of tumors of the rectum and anal canal. AJR Am J Roentgenol; 2008 Jun;190(6):1495-504
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspective on the role of transrectal and transvaginal sonography of tumors of the rectum and anal canal.
  • OBJECTIVE: Intestinal sonography is characterized by excellent resolution of the multiple layers of the intestinal wall and sensitive depiction of the degree of invasion of rectal tumors.
  • Our purpose is to describe the current status of sonography in the evaluation of rectal and anal tumors and in the staging of rectal cancer.
  • They are considered the reference standard for the preoperative staging of rectal and anal cancers and have relatively high accuracy in categorization of tumors and nodes in TNM staging.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Image Enhancement / methods. Rectal Neoplasms / ultrasonography. Rectum / ultrasonography. Vagina / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492898.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


7. Duensing A, Chin A, Wang L, Kuan SF, Duensing S: Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology; 2008 Mar 1;372(1):157-64
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms.
  • High-risk HPV-associated anal neoplasms are difficult to treat and biomarkers of malignant progression are needed.
  • However, a detailed analysis of centrosome overduplication in primary HPV-associated neoplasms has not been performed so far.
  • Here, we determined the frequency of centrosome overduplication in HPV-associated anal lesions using a recently identified marker for mature maternal centrioles, Cep170.
  • Remarkably, centrosome overduplication, but not aberrant centrosome numbers per se or centrosome accumulation, correlated significantly with the presence of cell division errors.
  • In addition, our experiments revealed that in particular pseudo-bipolar mitoses may play a role in the propagation of chromosomal instability in high-risk HPV-associated tumors.
  • These results provide new insights into the role of centrosome aberrations in cell division errors and encourage further studies on centrosome overduplication as a predictive biomarker of malignant progression in HPV-associated anal lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):190-6 [10662596.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2356-60 [11289095.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):M81-8 [11342187.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Inflamm Res. 2002 Aug;51(8):416-22 [12234059.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] Mol Cancer. 2003 Sep 8;2:30 [14498992.001]
  • [Cites] N Engl J Med. 1984 Apr 5;310(14):880-3 [6321986.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Curr Opin Oncol. 1995 Sep;7(5):437-41 [8541389.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Acta Oncol. 1997;36(1):3-12 [9090961.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Jun;104(6):723-7 [9197877.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):233-40 [9258658.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4210-3 [9331077.001]
  • [Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):15-20 [9709296.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1095-107 [15616186.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):352-9 [15890539.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1043-7 [16222300.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):74-8 [16361091.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2899-902 [17172866.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):215-21 [17383880.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63 [17505520.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6280-8 [17438528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10002-7 [10944189.001]
  • (PMID = 18036631.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112598-03; United States / NCI NIH HHS / CA / R01 CA112598; United States / NCI NIH HHS / CA / R01 CA 112598; United States / NCI NIH HHS / CA / R01 CA112598-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cep170 protein, human; 0 / Phosphoproteins; 0 / Tubulin
  • [Other-IDs] NLM/ NIHMS38243; NLM/ PMC2267749
  •  go-up   go-down


8. Meyer JJ, Willett CG, Czito BG: Emerging role of intensity-modulated radiation therapy in anorectal cancer. Expert Rev Anticancer Ther; 2008 Apr;8(4):585-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although radiation therapy has an established role to play in the management of rectal and anal tumors, there are often treatment-related morbidities that negatively impact on patients.
  • It has been implemented in the treatment of prostate and head and neck tumors with success.
  • This article reviews the rationale for its use in treating anorectal tumors and discusses early clinical data supporting its continued investigation.
  • [MeSH-major] Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402525.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 58
  •  go-up   go-down


9. Martellucci J, Naldini G, Colosimo C, Cionini L, Rossi M: Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc; 2009 May;23(5):1054-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy.
  • BACKGROUND: Radiochemotherapy has largely replaced surgery in the treatment for squamous cell cancer of the anal canal.
  • Transanal ultrasonography is well documented as an important investigation method in the management of anal carcinoma.
  • This study aimed to evaluate the accuracy of endoanal ultrasound in the study of the postradiation findings and to distinguish between postradiation fibrosis, residual tumor, and local recurrence.
  • METHODS: The study enrolled 16 consecutive patients with biopsy-proven squamous carcinoma of the anal canal between 2003 and 2006.
  • RESULTS: Nine patients had stage uT2 disease; none had uT3 disease; and seven had uT4 disease.
  • There was no evidence of residual tumor in the T2 group after treatment.
  • In the T4 patients after treatment, ultrasound demonstrated tumor regression or abnormalities considered to be radiation-induced changes rather than residual diseases.
  • CONCLUSIONS: Endoanal ultrasound is a safe and effective method for evaluating and following anal cancer before and after treatment.
  • Experience and evaluation during the period of the ultrasonographic abnormalities could give a clear idea concerning the evolution of the anal tumors treated with radiochemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Carcinoma, Squamous Cell / diagnostic imaging. Endosonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):77-92 [12098609.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):359-64 [10433044.001]
  • [Cites] Surg Clin North Am. 2004 Aug;84(4):1127-49, vii [15261756.001]
  • [Cites] Surg Endosc. 1994 Oct;8(10 ):1186-9 [7809802.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):839-42 [15085443.001]
  • [Cites] Eur J Radiol. 2003 Aug;47(2):142-8 [12880995.001]
  • (PMID = 18813993.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Pérez Pereyra J, Frisancho Velarde O, Ruiz Barahona E, Palomino A: [Fibroepithelial lesions of the anal canal: therapeutic technique with rubber band ligation]. Rev Gastroenterol Peru; 2008 Jan-Mar;28(1):37-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibroepithelial lesions of the anal canal: therapeutic technique with rubber band ligation].
  • [Transliterated title] Lesiones Fibroepiteliales del Canal Anal: alternativa terapéutica con ligadura de bandas elásticas.
  • When fibroepithelial lesions of the anal canal increase in size and bleed, they can produce tenesmus and a sensation of a foreign body in the anus.
  • In the Gastroenterology Department of the "Edgardo Rebagliati Martins" National Hospital (EsSALUD) between June 2000, and June, 2007, 16 patients with anal fibroepithelioma were included: 6 men and 10 women, with an average age of 44, aged between 21 to 75, and 44% aged 20 to 29.
  • All of these patients (100%) had anal tumors, 50% had prolapses, 28% had anal pain and, 12% intermittent slight bleeding.
  • Patients only required oral analgesics for the first hours after procedure; only one patient presented an acute anal fissure.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Fibroepithelial / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418455.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


11. Hosono S, Ohira M, Maeda K, Muguruma K, Nishihara T, Inoue T, Yashiro M, Hirakawa K: Synchronous adenocarcinomas of the ileum and transverse colon detected by capsule endoscopy: report of a case. Surg Today; 2006;36(7):663-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither gastrointestinal endoscopy nor computed tomography showed by abnormal findings; however, a capsule endoscopy, performed to detect obscure gastrointestinal bleeding, revealed a tumor in the ileum.
  • When we tried to take biopsies of the ileal tumor by push enteroscopy via the anus, we found another tumor in the transverse colon.
  • On exploration, tumors were identified in the ileum and the transverse colon.
  • [MeSH-major] Adenocarcinoma / pathology. Capsule Endoscopy. Colonic Neoplasms / pathology. Ileal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):255-61 [15729235.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Scand J Gastroenterol. 2005 Jun;40(6):725-33 [16036534.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1060-6 [15578295.001]
  • [Cites] Indiana Med. 1991 Jun;84(6):392-6 [1918906.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Can J Gastroenterol. 2004 Sep;18(9):559-65 [15457295.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jan;14(1):51-60 [15062380.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Endoscopy. 2004 Jan;36(1):32-41 [14722853.001]
  • [Cites] Gut. 2003 Aug;52(8):1122-6 [12865269.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • (PMID = 16794807.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • However, the treatment response was graded as progressive disease, and the treatment was changed from CDDP to mitomycin C (MMC).
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


13. Baatrup G, Bolstad M, Mortensen JH: Rigid sigmoidoscopy and MRI are not interchangeable in determining the position of rectal cancers. Eur J Surg Oncol; 2009 Nov;35(11):1169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE:. 1) To analyse for interchangeability of rigid sigmoidoscopy and MRI in determining the distance from anus to tumour, and to determine if anterior/posterior location influences this difference.
  • 2) To analyse the effect of preoperative chemo-radiotherapy on the distance from anus to tumour.
  • RESULTS: The mean distance from the anal verge to the tumour measured by sigmoidoscopy was 82mm and by MRI 61mm (p<0.01).
  • The length of the tumours decreased by 16mm after neoadjuvant treatment, but the distance from tumour to anus increased by only 4mm. CONCLUSION:.
  • 1) MRI and sigmoidoscopy are not interchangeable in determining the distance from anus to tumour simply by correcting for the length of the anal canal.
  • 2) The gain in tumour free distance above the anus induced by neoadjuvant treatment is small.
  • [MeSH-major] Anal Canal / pathology. Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249188.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


15. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Partial tumor regression was registered in 46 of 120 patients.
  • The abdominoperineal resection was performed in 39(84.8%) of patients with the residual tumor.
  • Thus, surgical treatment allowed secondary local tumor control in 76.9% of patients with the 5-year survival rates of 69.0%.
  • The locoregional tumor relapse was diagnosed in 10(13.74%) of 74 patients with the complete tumor regression.
  • The use of abdominoperineal resection allowed the secondary local tumor control and 5 year survival.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Russia / epidemiology. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


16. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lustberg MB, Nuovo J, Thomas JP, Monk PJ 3rd, Kim S, Villalona-Calero M, Bekaii-Saab T: Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):2569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study.
  • : 2569 Background: A principal determinant of the therapeutic index with capecitabine-based treatment is the grade of thymidine phosphorylase (TP) activity in malignant tissue.
  • The beneficial interactions of paclitaxel and carboplatin in upregulation of TP promise to make capecitabine more tumor specific and to provide the expected synergy.
  • METHODS: Patients with advanced solid tumors received carboplatin on day 1, paclitaxel on days 1, 8, 15 and capecitabine orally twice a day on days 8-21, every 4 weeks.
  • There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mita MM, Tolcher A, Gordon MS, Rosen L, Mita A, Fine G, Choy G, Berk G: A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):e13511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients.
  • : e13511 Background: MP-470 (MP) is an oral multi-targeted tyrosine kinase inhibitor which inhibits a number of validated tumor targets including c-kit, flt3, and PDGFα.
  • Adults with ECOG PS of 0-2 and malignant disease appropriate for SOC regimens consisting of paclitaxel/carboplatin (PC), carboplatin/etoposide (CE), topotecan, docetaxel, and erlotinib were enrolled.
  • Six PRs (2 neuroendocrine, 2 SCLC, 1 NSCLC, 1 small cell of anal canal) and 3 SDs (≥ 4 cycles) was observed.
  • CONCLUSIONS: MP470 combined with carboplatin-containing regimens may promote tumor regression and may also sensitize/resensitize tumors to the anticancer effects of such agents.
  • An amendment will be issued to collect tumor tissue biopsy at baseline and during treatment to adequately evaluate DNA damage in tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R: A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors.
  • Pre-clinical studies demonstrate that vorinostat down-regulates intra-tumor TS in a dose-dependent fashion and augments 5-FU antitumor activity in xenograft models.
  • We conducted a phase I clinical trial of an intermittent schedule of QD x 3 vorinostat in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with refractory solid tumors.
  • METHODS: Vorinostat was escalated in a standard 3 x 3 design in combination with a fixed dose of 5-FU and LV (simplified de Gramont regimen, sFULV2).
  • 21 pts had colorectal cancer (CRC), 1 had gastric, 1 had esophageal, and 1 had anal cancer.
  • An expanded MTD cohort is accruing to investigate 5-FU-vorinostat PK interaction and intra-tumor TS down-regulation. (This work was supported by a grant from CTEP and the ACS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dickson MA, Carvajal RD, Shah M, Tse AN, Dials H, Cane LM, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol. J Clin Oncol; 2009 May 20;27(15_suppl):e14511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a phase I trial of FOLFIRI + F every 2 weeks in patients (pts) with advanced solid tumors.
  • Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head & neck, unknown primary.
  • 22 pts had stable disease (median 5.9 m; range 1.5-25.7 m).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Velenik V, Ocvirk J, Oblak I, Anderluh F: Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The radiosensitizing effect of cetuximab, an EGFR-targeting monoclonal antibody, may further enhance the tumor response.
  • Tumor regression grades (TRG) were evaluated on surgical specimens according to Dworak.
  • Three pts (8.1%) had T3N0 tumors, 1 pt (2.7%) T2N1, 13 pts (35%) T3N1, 1 pt (2.7%) T2N2, 15 pts (40.5%) T3N2 and 4 pts (11%) T4N2.
  • The median tumor distance from anal verge was 6 (range: 1-11) cm.
  • The total sphincter preservation rate was 75.7%; in 17 pts whose tumors were located ≤5 cm of the anal verge, the rate was 53%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST).
  • : 10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Average tumor size was 10.5 cm (4-28 cm).
  • According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour.
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Of the remaining 33, median tumor size shrank to 55 mm.
  • Complete tumor removal was possible in 28 pts without operative mortality, but two pts showed previously undetected peritoneal spread (R2 resection).
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).
  • Substantial tumor shrinkage facilitates radical but conservative surgery and results in organ-preservation in the overwhelming majority of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Divis P, Vlcek P, Capov I, Divisová K, Katolická J, Vanícek J, Kotulánová E: [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment]. Klin Onkol; 2010;23(6):421-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment].
  • The aim of the study was to compare the tumour volume reduction before and after the oncological therapy in relation to the change in the CEA value and to the outcome of the histopathological evaluation of response to the treatment.
  • The tumour volume before and after the CRT, percentage reduction in the tumour volume and the relation to the change in the CAE value and the histopathological evaluation were evaluated.
  • RESULTS: The distance between the anus and the tumour was from 3 to 15 centimetres, the average value being 8.1 centimetres.
  • In 5 cases the tumour was not histologically found in the resected specimen.
  • The average tumour volume before CRT was 32.48, range 10.3-88.5, after the CRT the average volume was 20.13, range 4.7-55.1.
  • This relation however has not been proved in the N value change.
  • Only in one-third of the evaluated patients was there a positive change in both T and N classification.
  • No relation between the CEA value and the tumour volume change has been proven.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Neoadjuvant Therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351419.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


24. Palefsky J: Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep; 2008 May;5(2):78-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and anal neoplasia.
  • Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection.
  • Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women.
  • Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).
  • HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer.
  • Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Papillomavirus Infections
  • [MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomaviridae / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510893.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


25. Shia J: An update on tumors of the anal canal. Arch Pathol Lab Med; 2010 Nov;134(11):1601-11
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on tumors of the anal canal.
  • CONTEXT: The anal canal possesses complex anatomy and histology and gives rise to a variety of tumor types.
  • Challenging issues remain with regard to both the pathologic diagnosis and the clinical management of these tumors.
  • OBJECTIVES: To provide an updated overview of the histogenesis, clinical and pathologic characteristics, diagnostic terminology, and relevant clinical management of the various types of anal canal tumors.
  • DATA SOURCES: Recent literature on clinical and pathologic characteristics of anal canal tumors.
  • CONCLUSIONS: Although most anal canal tumors are of squamous lineage, a complex variety of other tumors also occurs.
  • Recognition of such diverse tumor entities will allow accurate pathologic diagnosis and most optimal clinical management.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043813.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


26. Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV: Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum; 2005 Dec;48(12):2289-93
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases.
  • The analysis of our patients suggests that herpes simplex virus, Types 1 and 2, may cause verrucous lesions simulating neoplasia in patients with AIDS using antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / diagnosis. Herpes Simplex / diagnosis
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Humans. Hypertrophy. Immunohistochemistry. Inflammation. Male. Middle Aged. Recurrence


27. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • [Transliterated title] Pathologie tumorale anale et péri-anale.
  • Tumors of the anal canal and anal margin are rare.
  • Benign tumors mainly consist of condylomas, cloacogenic polyps and fibro-epithelial polyps.
  • The other malignant tumors are very rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


28. Poizot-Martin I, Henry M, Benhaim S, Obry-Roguet V, Figarella D, Tamalet C: High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients. J Clin Virol; 2009 Apr;44(4):314-7
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients.
  • BACKGROUND: Despite HAART, the prevalence and incidence of anal cancer in HIV-infected individuals have increased.
  • Recently, the relationship between the severity of cervical lesions and oncogenic HPV load was demonstrated; however, few studies have assessed the level and the significance of oncogenic HPV load in patients at risk for anal neoplasia.
  • OBJECTIVES: To assess HPV genotypes and HPV 16/18 DNA load in HIV-1 infected patients at risk for anal neoplasia.
  • STUDY DESIGN: Cross-sectional pilot study from male and female HIV-1 infected individuals at risk for anal neoplasia in an outpatient HIV Clinical Unit of Marseilles university Hospitals.
  • RESULTS: Anal HPV was found in 79% of the patients whereas high-risk (HR) HPV types and infection with multiple HPV types were found in 83% and 61% of the patients, respectively.
  • CONCLUSIONS: Longitudinal studies are needed to evaluate the link between high anal HPV DNA load and progression to anal squamous intraepithelial lesions and anal cancer.
  • [MeSH-major] Anal Canal / virology. DNA, Viral / isolation & purification. HIV Infections / complications. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269245.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


29. Danova NA, Robles-Emanuelli JC, Bjorling DE: Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs. Vet Surg; 2006 Jun;35(4):337-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs.
  • OBJECTIVE: To describe an anal approach for excision of primary rectal tumors in dogs and to report outcome.
  • ANIMALS: Dogs (n=23) with primary rectal tumors.
  • METHODS: Review of medical records (1990-2000) of dogs with primary rectal neoplasia excised surgically using an anal approach with rectal prolapse.
  • With dogs anesthetized, the rectum was prolapsed, stabilized with stay sutures during tumor excision with 1 cm margins to the level of the muscularis, then the rectal mucosa was sutured.
  • RESULTS: Each dog had only 1 tumor type (adenocarcinoma [8], solitary polyp [5], carcinoma [4], plasmacytoma [2], adenoma [1], leiomyoma [1], mucinous carcinoma [1], and papilloma [1]).
  • Mean tumor volume was 3.1 cm(3) (range 0.1-37.7 cm(3)).
  • The primary tumor was incompletely excised in 1 dog (4.3%), and local recurrence occurred 16 and 24 months after surgery in 2 dogs.
  • Mean postoperative disease-free interval for these 18 dogs was 36.8 months (range 5-84 months).
  • CONCLUSION: Surgical excision of tumors of the caudal rectum can be accomplished through the anus after rectal prolapse.
  • CLINICAL RELEVANCE: An anal approach facilitated by rectal prolapse should be considered as a viable option for the surgical treatment of selected cases of tumors of the caudal aspect of the rectum in dogs.
  • [MeSH-major] Anal Canal / surgery. Dog Diseases / surgery. Rectal Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / surgery. Adenocarcinoma / veterinary. Animals. Disease-Free Survival. Dogs. Female. Male. Polyps / surgery. Polyps / veterinary. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Treatment Outcome. Wisconsin / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756613.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F: Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl Tumori; 2005 May-Jun;4(3):S31
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
  • This paper reports six patients with perianal Crohn's disease (CD), who developed anal cancer in chronic anal fistulas.
  • Tumors have been often diagnosed at an advanced stage and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
  • Patients with perianal CD should undergo a careful surveillance program for ano-rectal carcinoma, including routine biopsy of any suspected lesion.
  • [MeSH-major] Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437885.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Hwang HJ, Bestani C, Jiménez R, Masciángioli G, Gutiérrez A, Cartelli C, Rafailovici L, Barugel M, Rodríguez G, Méndez G: [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital]. Acta Gastroenterol Latinoam; 2005;35(2):94-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].
  • [Transliterated title] El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital.
  • Anal cancers compromise only 1.5% of all digestive tumors.
  • OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with squamous cell carcinoma of the anal canal (SCCAC) treated by the Oncology Section in 20 years.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127985.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


32. Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, Li S, McCollum N, Ferrara A, Gallagher JT, Baker CH: Novel murine model for colon cancer: non-operative trans-anal rectal injection. J Surg Res; 2009 Jun 15;154(2):299-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel murine model for colon cancer: non-operative trans-anal rectal injection.
  • Different magnifications (10x versus 100x) were used for injection, and primary tumor growth and metastatic disease were studied.
  • RESULTS: In the initial study, 3/7 mice injected using 10x magnifications had notable, large tumor originating from the rectal wall, and histology revealed that all excised tumors were poorly differentiated adenocarcinoma.
  • In the second study, 8/10 mice injected using 100x magnifications had notable tumor originating from the rectal well, and 4/8 mice had abnormal lung tissue with pathological evidence of hemorrhagic pulmonary edema.
  • The use of 10x magnification resulted in 43% tumor take.
  • In sharp contrast, 80% tumor take was observed with 100x magnification.
  • The overall success of tumor take was 65% using the trans-anal rectal injection model.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Disease Models, Animal. Mice, Inbred BALB C. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Differentiation. Cell Line, Tumor. Injections / methods. Lung / pathology. Lung Neoplasms / secondary. Mice. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101690.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • Details of CRT, surgery, tumor characteristics, postoperative complications, and survival were obtained from medical records.
  • Initial tumors were AJCC stage 2 (16 cases), 3A (3 cases), and 4 (1 case).
  • Tumor differentiation (p=0.02) and positive resection margins (p=0.004) were significantly associated with DFS (5-year DFS of 37%).
  • Salvage APR in patients with poorly differentiated tumors or positive resection margins has a high morbidity and poor survival and may warrant a planned APR after CRT instead.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Survival Analysis. Treatment Failure


34. Cotter SE, Grigsby PW, Siegel BA, Dehdashti F, Malyapa RS, Fleshman JW, Birnbaum EH, Wang X, Abbey E, Tan B, Kodner IJ, Hunt SR, Lowney JK, Mutch MG, Dietz DW, Myerson RJ: FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):720-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT in the evaluation of anal carcinoma.
  • PURPOSE: Surgical staging and treatment of anal carcinoma has been replaced by noninvasive staging studies and combined modality therapy.
  • In this study, we compare computed tomography (CT) and physical examination to [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the staging of carcinoma of the anal canal, with special emphasis on determination of spread to inguinal lymph nodes.
  • METHODS AND MATERIALS: Between July 2003 and July 2005, 41 consecutive patients with biopsy-proved anal carcinoma underwent a complete staging evaluation including physical examination, CT, and 2-FDG-PET/CT.
  • RESULTS: [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) detected 91% of nonexcised primary tumors, whereas CT visualized 59%.
  • CONCLUSION: [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography detects the primary tumor more often than CT.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626889.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Martínez-Hernández-Magro P, Villanueva-Sáenz E, Chávez-Colunga LB: [Anal malignant melanoma. Case report and literature review]. Rev Gastroenterol Mex; 2009;74(1):39-44
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal malignant melanoma. Case report and literature review].
  • [Transliterated title] Melanoma maligno anal. Reporte de casos y revisión de la literatura.
  • OBJECTIVE: To present two cases of anorectal malignant melanoma as due to its non specific presentation and rarity they are often misdiagnosed like hemorrhoids.
  • BACKGROUND: Anal melanomas are rare tumors that constitute less than 1% of the malignant colorectal tumors and represent both a diagnostic and therapeutic challenge to physicians.
  • Melanomas are often misdiagnosed by a lot of anorectal conditions and diagnosis must be suspected in patients with an anal mass.
  • CASE REPORT: We present two anorectal cases of malignant melanoma treated by wide local excision, the principal complain in both patients was the presence of an anal mass and bleeding.
  • CONCLUSIONS: Anal melanoma is a rare entity with a poor prognosis.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666318.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  •  go-up   go-down


36. Menkarios C, Azria D, Laliberté B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Aillères N, Fenoglietto P: Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol; 2007;2:41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans.
  • BACKGROUND: To compare the dosimetric advantage of three different intensity-modulated radiation therapy (IMRT) plans to a three dimensional (3D) conventional radiation treatment for anal cancer with regards to organs-at-risk (OAR) avoidance, including iliac bone marrow.
  • METHODS: Five patients with T1-3 N0-1 anal cancer and five with T4 and/or N2-3 tumors were selected.
  • Clinical tumor volume (CTV) included tumor, anal canal and inguinal, peri-rectal, and internal/external iliac nodes (plus pre-sacral nodes for T4/N2-3 tumors).
  • CONCLUSION: IMRT is superior to 3D conformal radiation treatment for anal carcinoma with respect to OAR sparing, including bone marrow sparing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2006 Oct;176(4 Pt 1):1415-9 [16952647.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(1):82-6 [16983394.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):160-6 [17222931.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39 [7713791.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1731-6 [8625041.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16 [11240231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):275-80 [11730997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1388-96 [12459361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Phys Med Biol. 1961 Jan;5:255-8 [13726497.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):274-81 [16111597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • (PMID = 18005443.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2204019
  •  go-up   go-down


37. Järvelä S, Parkkila S, Bragge H, Kähkönen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H: Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer; 2008;8:1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX in oligodendroglial brain tumors.
  • METHODS: This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed oligoastrocytomas).
  • RESULTS: 80% of the tumors showed CA IX expression by immunohistochemistry.
  • Tumors with moderate or strong CA IX expression had decreased level of cell proliferation compared to weak or no CA IX expression (median 2.9 vs. 5.8, p = 0.015).
  • CA IX correlated with two antioxidative enzymes, manganese superoxide dismutase (MnSOD) and regulatory gammaglutamylcysteine synthetase (GLCL-R): CA IX expression was significantly higher in MnSOD-positive tumors (p = 0.008) and decreased in GLCL-R-positive tumors (p = 0.044).
  • CONCLUSION: CA IX was proved to be an independent prognostic indicator in oligodendroglial brain tumors, and it also correlates reversely with cell proliferation.
  • It may have a role in the biology of oligodendrogliomas, and most interestingly, as it is mainly expressed in tumor tissue, CA IX could serve as a target molecule for anticancer treatments.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism. Oligodendroglioma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6567-71 [15475445.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):398-408 [9024293.001]
  • [Cites] Cancer Res. 1982 May;42(5):1955-61 [7066906.001]
  • [Cites] Am J Med. 1991 Sep 30;91(3C):14S-22S [1928205.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Aug;16(4):261-8 [7524516.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):279-85 [9665489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1197-207 [15752902.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Nov 1;15(21):4872-6 [16165351.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1750-7 [11410516.001]
  • [Cites] Mol Hum Reprod. 2001 Jul;7(7):611-6 [11420383.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:421-55 [11441809.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):643-9 [11690711.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):29-37 [11804280.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1205-12 [11861405.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Apr;28(2):89-94 [11972795.001]
  • [Cites] Med Res Rev. 2003 Mar;23(2):146-89 [12500287.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):155-64 [12744469.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600-19 [12796054.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23 [14684331.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):995-1004 [15010840.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):869-73 [15012984.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • (PMID = 18173856.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2245965
  •  go-up   go-down


38. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg; 2007 Nov;11(11):1410-5; discussion 1415-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.
  • Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.
  • We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.
  • Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.
  • Patients with disease amenable to local therapy were treated with office-based HRA-directed therapies.
  • HSIL was present in 33, with four undergoing planned staged treatment due to circumferential disease.
  • HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710507.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Meropol NJ, Niedzwiecki D, Shank B, Colacchio TA, Ellerton J, Valone F, Budinger S, Day JM, Hopkins J, Tepper J, Goldberg RM, Mayer RJ: Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol; 2008 Jul 01;26(19):3229-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
  • PURPOSE: Although most patients with anal canal cancer are cured with sphincter-preserving, nonsurgical, combined-modality therapy, those with large tumors and lymph node involvement have a poor prognosis.
  • To establish the safety and efficacy of induction chemotherapy with infusional fluorouracil (FU) plus cisplatin followed by FU plus mitomycin C with concurrent radiation in patients with poor-prognosis squamous cell cancers of the anal canal.
  • METHODS: Patients with previously untreated anal canal cancers with T3 or T4 tumors and/or extensive nodal involvement (bulky N2 or N3) received two 28-day cycles of induction treatment with infusional FU plus cisplatin followed by two 28-day cycles of FU plus mitomycin C with concurrent split-course radiation.
  • A third cycle of FU and cisplatin with radiation boost was given to patients with persistent primary site disease or bulky N2 or N3 disease at presentation.
  • After 4 years of follow-up, 68% of patients are alive, 61% are disease-free, and 50% are colostomy- and disease-free.
  • CONCLUSION: A combined-modality approach that includes induction treatment with FU and cisplatin followed by combined-modality therapy with FU, mitomycin C, and concurrent radiation results in long-term disease control in the majority of patients with poor-prognosis anal canal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA35421; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Habib SL, Simone S, Barnes JJ, Abboud HE: Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors. Mol Cancer; 2008 Jan 24;7:10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors.
  • BACKGROUND: Tuberous sclerosis complex (TSC) is caused by defects in one of two tumor suppressor genes, TSC-1 or TSC-2.
  • TSC-2 gene encodes tuberin, a protein involved in the pathogenesis of kidney tumors.
  • We investigated the distribution of protein expression and the activity of OGG1 and 8-oxo-dG and correlated it with the expression of tuberin in kidneys of wild type and Eker rats and tumor from Eker rat.
  • In kidney tumors from Eker rats, the loss of the second TSC2 allele is associated with loss of OGG1 expression.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3523-8 [11904416.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jan;294(1):F281-90 [17989114.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):573-82 [12663520.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):561-70 [15130282.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Urol. 1984 Dec;132(6):1170-4 [6502814.001]
  • [Cites] J Urol. 1987 Sep;138(3):477-81 [3625844.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):166-72 [1730583.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1693-5 [1553556.001]
  • [Cites] J Biol Chem. 1993 Nov 5;268(31):23524-30 [8226881.001]
  • [Cites] Biochimie. 2000 Jan;82(1):59-64 [10717388.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4740-4 [10987279.001]
  • [Cites] Regul Toxicol Pharmacol. 2000 Dec;32(3):264-75 [11162720.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):65-9 [11295288.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5378-81 [11454679.001]
  • [Cites] Environ Mol Mutagen. 2001;38(2-3):180-90 [11746753.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):15318-24 [7515054.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):181-97 [9644327.001]
  • [Cites] Oncogene. 1998 Jun 11;16(23):3083-6 [9662341.001]
  • [Cites] Jpn J Cancer Res. 1998 Aug;89(8):825-8 [9765618.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2208-16 [9827727.001]
  • [Cites] J Histochem Cytochem. 1999 Apr;47(4):533-44 [10082755.001]
  • [Cites] DNA Repair (Amst). 2006 Nov 8;5(11):1337-45 [16861056.001]
  • [Cites] DNA Repair (Amst). 2007 Apr 1;6(4):544-59 [17112792.001]
  • [Cites] Toxicol Pathol. 2002 Nov-Dec;30(6):675-80 [12512868.001]
  • (PMID = 18218111.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P50 DK061597; United States / NIDDK NIH HHS / DK / R37 DK33665
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / OGG1 protein, rat; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2265742
  •  go-up   go-down


41. von Roon AC, Tekkis PP, Clark SK, Heriot AG, Lovegrove RE, Truvolo S, Nicholls RJ, Phillips RK: The impact of technical factors on outcome of restorative proctocolectomy for familial adenomatous polyposis. Dis Colon Rectum; 2007 Jul;50(7):952-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes were major complications, pouch function, and neoplastic transformation in the anal transitional zone.
  • The incidence of polyps at the anal transitional zone was lower with handsewn than with stapled anastomosis (19 vs. 38 percent; P=0.047).
  • Handsewn ileoanal anastomosis with mucosectomy seems to reduce the incidence of subsequent neoplasia in the anal transitional zone but does not eliminate the risk of cancer.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Incidence. Length of Stay. Male. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome


42. Ozcan A, Deveci MS, Oztas E, Dede M, Yenen MC, Korgun ET, Gunhan O: Prognostic value of GLUT-1 expression in ovarian surface epithelial tumors: a morphometric study. Anal Quant Cytol Histol; 2005 Aug;27(4):181-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of GLUT-1 expression in ovarian surface epithelial tumors: a morphometric study.
  • OBJECTIVE: To investigate the reported increase in the expression of the glucose transporter GLUT-1 in borderline and malignant ovarian epithelial tumors and its relationship to prognosis.
  • STUDY DESIGN: In this study, areas in which immunohistochemical membranous staining with GLUT-1 were most evident were selected, and the proportions of GLUT-1 expression in 46 benign, 11 borderline and 42 malignant cases of ovarian epithelial tumors were determined quantitatively with a computer and Zeiss Vision KS 400 3.0 (Göttingen, Germany) for Windows (Microsoft, Redmond, Washington, U.S.A.) image analysis.
  • RESULTS: GLUT-1 expression was determined in all borderline tumors (11 of 11) and in 97.6% of malignant tumors (41 of 42).
  • No GLUT-1 expression was observed in benign tumors.
  • The intensity of GLUT-1 staining was lower in borderline tumors than in malignant cases.
  • As differentiation in malignant tumors increased, proportions of GLUT-1 expression showed a relative increase, but this difference was not statistically significant (p = 0.68).
  • CONCLUSION: When GLUT-1 expression in borderline and malignant ovarian epithelial tumors was analyzed against prognosis, no statistically significant difference was identified.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220828.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


43. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods
  • [MeSH-minor] Adult. Biopsy. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G: Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3355-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma.
  • PURPOSE: Tumor-infiltrating lymphocytes (TIL) are a possible prognostic factor in solid tumors.
  • We have evaluated the effect of T-cell subsets on survival in patients with anal squamous cell carcinoma following radiochemotherapy.
  • METHODS: Biopsy specimens from 38 patients with anal carcinomas were evaluated using tissue microarrays and immunohistochemistry for the presence of tumor-infiltrating immune cells using CD3, CD4, CD8, and CD68 antibodies.
  • Prognostic effect of TIL subsets was evaluated by the log-rank test comparing no evidence of disease survival for groups with high and low numbers using median values as cutoff.
  • RESULTS: CD3+ and CD4+ TILs influenced no evidence of disease survival: 3-year rates for patients with low numbers were 89% and 95%, respectively, and 54% (P = 0.02) and 48%, (P = 0.01), respectively, in cases with high numbers.
  • Large numbers of tumor-infiltrating granzyme B+ cytotoxic cells had a significant negative prognostic effect (P = 0.008), whereas no effect was observed for Treg.
  • CONCLUSIONS: TILs were identified as negative prognostic indicators in anal squamous cell carcinomas with granzyme B+ cytotoxic cells showing highest effect on outcome.
  • This is possibly explained by the selection of therapy-resistant tumor cell clones.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Regulatory / immunology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740757.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Sahai A, Kodner IJ: Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg; 2006 May;19(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.
  • Premalignant and malignant lesions of the anal margin are rare.
  • Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.
  • Combined multimodality treatment has come to play an important role in managing patient with more advanced or metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]
  • [Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]
  • [Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]
  • (PMID = 20011315.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780101
  • [Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer
  •  go-up   go-down


46. Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF: Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila); 2010 Dec;3(12):1542-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin inhibits anal carcinogenesis in two preclinical animal models.
  • The incidence of anal cancer is increasing especially among HIV-infected persons in the HAART era.
  • Treatment of this cancer is based upon traditional chemoradiotherapeutic approaches, which are associated with high morbidity and of limited effectiveness for patients with high-grade disease.
  • In archival human anal cancers, we observed mTOR pathway activation.
  • To assess response of anal cancer to mTOR inhibition, we utilized two newly developed mouse models, one in which anal cancers are induced to arise in HPV16 transgenic mice and the second a human anal cancer xenograft model.
  • Using the transgenic mouse model, we assessed the preventative effect of rapamycin on neoplastic disease.
  • We saw significant changes in the overall incidence of tumors, and tumor growth rate was also reduced.
  • Using both the transgenic mouse and human anal xenograft mouse models, we studied the therapeutic effect of rapamycin on preexisting anal cancer.
  • Rapamycin was found to significantly slow, if not stop, the growth of both mouse and human anal cancers.
  • These results provide us cause to pursue further the evaluation of rapamycin as a therapeutic agent in the control of anal cancer.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9953-61 [16267020.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Dec;3(12):1534-41 [20947489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9393-400 [17018593.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10040-7 [17047067.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2160-8 [17332346.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2281-9 [17404113.001]
  • [Cites] Oncogene. 2007 May 17;26(23):3321-8 [17130828.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4964-73 [17785546.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] J Invest Dermatol. 2008 Apr;128(4):980-7 [17914450.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2622-31 [18413729.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):446-57 [18058806.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13 [17912526.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3065-74 [18725988.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2 [18926092.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3373-81 [11309295.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):721-6 [1102508.001]
  • [Cites] Can J Physiol Pharmacol. 1977 Feb;55(1):48-51 [843990.001]
  • [Cites] Immunology. 1991 Apr;72(4):544-9 [1709916.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):903-7 [7508822.001]
  • [Cites] Circ Res. 1995 Mar;76(3):412-7 [7532117.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2490-5 [15699322.001]
  • [Cites] J Virol. 2005 Apr;79(7):3938-48 [15767396.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9928-34 [19047174.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jan;2(1):27-36 [19139015.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):589-96 [19147764.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Nat Rev Immunol. 2009 May;9(5):324-37 [19390566.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4407-14 [19435895.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4159-66 [19435901.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5656-63 [19584294.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19467-72 [19901334.001]
  • [Cites] Semin Oncol. 2009 Dec;36 Suppl 3:S46-58 [19963100.001]
  • [Cites] Cancer Res. 2010 Apr 1;70(7):2924-31 [20332225.001]
  • [Cites] Cancer Res. 2010 Jun 15;70(12):5064-73 [20530688.001]
  • [Cites] Int J Oncol. 2010 Oct;37(4):1001-10 [20811722.001]
  • [Cites] Virology. 2010 Nov 10;407(1):60-7 [20797753.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1183-9 [16731750.001]
  • (PMID = 21149330.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA090217-07; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / CA141583-03; United States / NCI NIH HHS / CA / CA141583-02; United States / NIDCR NIH HHS / DE / R01 DE017315-03; United States / NCI NIH HHS / CA / CA090217-07; United States / NCI NIH HHS / CA / T32 CA090217-06; United States / NCI NIH HHS / CA / U01 CA141583-03; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA090217-06; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / T32 CA090217-05; United States / NCI NIH HHS / CA / CA090217-05; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS249482; NLM/ PMC3058330
  •  go-up   go-down


47. Banovac F, Cheng P, Campos-Nanez E, Kallakury B, Popa T, Wilson E, Abeledo H, Cleary K: Radiofrequency ablation of lung tumors in swine assisted by a navigation device with preprocedural volumetric planning. J Vasc Interv Radiol; 2010 Jan;21(1):122-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of lung tumors in swine assisted by a navigation device with preprocedural volumetric planning.
  • MATERIALS AND METHODS: Simulated tumors were created in three live swine by percutaneously injecting agar nodules into the lung.
  • A treatment plan was devised for each tumor with optimization software to solve the planning problem.
  • The desired output was the minimum number of overlapping ablation spheres necessary to ablate each tumor and the margin.
  • RESULTS: A planning algorithm to spherically cover the tumors and the margin was computed.
  • Depending on their size, the tumors and the tumor margins were successfully covered with two to four ablation spheres.
  • CONCLUSIONS: Computer-assisted RF ablation planning and electromagnetically tracked probe insertion were successful in three swine, validating the feasibility of electromagnetic tracking-assisted tumor targeting.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jan;174(1):57-9 [10628454.001]
  • [Cites] J Digit Imaging. 2007 Nov;20 Suppl 1:21-33 [17703338.001]
  • [Cites] Radiology. 2000 Dec;217(3):633-46 [11110923.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):777-82 [11566672.001]
  • [Cites] J Urol. 2001 Nov;166(5):1827-8 [11586236.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):426-30 [12229953.001]
  • [Cites] Radiographics. 2002 Oct;22 Spec No:S259-69 [12376615.001]
  • [Cites] Br J Radiol. 2003 Oct;76(910):742-5 [14512336.001]
  • [Cites] Radiology. 2003 Dec;229(3):821-9 [14657317.001]
  • [Cites] Radiology. 2004 Jan;230(1):125-34 [14645875.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):207-12 [14761926.001]
  • [Cites] J Vasc Interv Radiol. 2004 May;15(5):463-70 [15126656.001]
  • [Cites] Radiology. 2004 Jun;231(3):850-7 [15105453.001]
  • [Cites] Radiology. 2004 Jul;232(1):260-71 [15166323.001]
  • [Cites] AJR Am J Roentgenol. 2004 Aug;183(2):361-8 [15269026.001]
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1003-11 [15385294.001]
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1013-20 [15385295.001]
  • [Cites] Acad Radiol. 1995 Sep;2(9):776-84 [9419639.001]
  • [Cites] Chest. 1998 Nov;114(5):1405-10 [9824022.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Oct;17(5):694-702 [9874293.001]
  • [Cites] Chest. 1999 Jul;116(1):139-43 [10424517.001]
  • [Cites] Cardiovasc Intervent Radiol. 1999 Sep-Oct;22(5):411-4 [10501894.001]
  • [Cites] Cardiovasc Intervent Radiol. 2004 Nov-Dec;27(6):581-90 [15578133.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):381-90 [15671350.001]
  • [Cites] Med Image Anal. 2005 Apr;9(2):163-75 [15721231.001]
  • [Cites] AJR Am J Roentgenol. 2005 Aug;185(2):466-71 [16037522.001]
  • [Cites] Med Phys. 2005 Aug;32(8):2698-705 [16193801.001]
  • [Cites] Phys Med Biol. 2006 Sep 7;51(17):4147-69 [16912374.001]
  • [Cites] Med Phys. 2006 Sep;33(9):3348-58 [17022231.001]
  • [Cites] J Vasc Interv Radiol. 2007 Sep;18(9):1141-50 [17804777.001]
  • [Cites] J Vasc Interv Radiol. 1999 Jan;10(1):92-5 [10872496.001]
  • (PMID = 19939704.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB007195-03; United States / NIBIB NIH HHS / EB / R01 EB007195; United States / NIBIB NIH HHS / EB / R01 EB007195-03; United States / NIBIB NIH HHS / EB / R01-EB007195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161655; NLM/ PMC2818540
  •  go-up   go-down


48. Borschitz T, Kiesslich R: Confocal chromolaser endomicroscopy: a supplemental diagnostic tool prior to transanal endoscopic microsurgery of rectal tumors? Int J Colorectal Dis; 2010 Jan;25(1):71-7
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal chromolaser endomicroscopy: a supplemental diagnostic tool prior to transanal endoscopic microsurgery of rectal tumors?
  • PURPOSE: Due to diagnostic advancements, preoperative staging of rectal tumors was significantly improved.
  • Cases with conflicting preoperative findings (adenoma vs. > or =uT2 categories), undetectable tumors after inadequate (R1/RX) snare polypectomy of carcinomas, and extremely flat adenoma areas were studied.
  • CONCLUSIONS: In cases with rectal tumors, conflicting or unclear findings, and flat extending adenomas, the utilization of cCLEM should be considered.
  • [MeSH-major] Anal Canal / surgery. Diagnostic Techniques and Procedures. Endoscopy / methods. Microscopy, Confocal / methods. Microsurgery / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Yi Xue Za Zhi. 2007 May 29;87(20):1417-9 [17785067.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1492-506; discussion 1500-5 [16897336.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):874-82 [17383417.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):445-50 [12925078.001]
  • [Cites] Zentralbl Chir. 2003 Dec;128(12):1066-74 [14750068.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):431-9 [14736677.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Br J Surg. 1985 Sep;72 Suppl:S51-2 [4041762.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):886-90 [16981104.001]
  • [Cites] Dis Colon Rectum. 2007 Mar;50(3):292-301 [17252286.001]
  • [Cites] Chirurg. 2004 Feb;75(2):168-75 [14991179.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):51-61 [12689670.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):562-9 [18070234.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8 [17294198.001]
  • [Cites] Gut. 2004 Feb;53(2):256-60 [14724160.001]
  • [Cites] Am J Surg. 2000 Apr;179(4):261-5 [10875982.001]
  • [Cites] Am J Surg. 2004 May;187(5):625-9; discussion 629 [15135679.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Oncology. 1996 Mar-Apr;53(2):89-93 [8604246.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):339-43 [16680631.001]
  • [Cites] Radiology. 2004 Sep;232(3):773-83 [15273331.001]
  • [Cites] Endoscopy. 2006 Nov;38(11):1110-4 [17111332.001]
  • [Cites] Dig Surg. 2004;21(4):287-92 [15308869.001]
  • [Cites] Z Gastroenterol. 2006 Aug;44(8):647-50 [16902894.001]
  • [Cites] Radiology. 2004 Aug;232(2):335-46 [15286305.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2882-91 [12115376.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):310-6 [17643705.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):10-5 [11786756.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1186-92 [16329015.001]
  • [Cites] Br J Surg. 2008 Apr;95(4):409-23 [18314929.001]
  • [Cites] Med Phys. 2005 Jun;32(6):1757-66 [16013733.001]
  • [Cites] Endoscopy. 2007 Apr;39(4):309-13 [17354183.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):144-9 [17591488.001]
  • [Cites] Gut. 2008 Feb;57(2):196-204 [18192453.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4141-6 [17696238.001]
  • [Cites] Am J Surg. 2006 Mar;191(3):410-2 [16490557.001]
  • [Cites] Endoscopy. 2007 Mar;39(3):216-21 [17385106.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1345-61 [11584215.001]
  • (PMID = 19888590.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Kokes R, Lister K, Gullapalli R, Zhang B, MacMillan A, Richard H, Desai JP: Towards a teleoperated needle driver robot with haptic feedback for RFA of breast tumors under continuous MRI. Med Image Anal; 2009 Jun;13(3):445-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Towards a teleoperated needle driver robot with haptic feedback for RFA of breast tumors under continuous MRI.
  • OBJECTIVE: The purpose of this paper is to explore the feasibility of developing a MRI-compatible needle driver system for radiofrequency ablation (RFA) of breast tumors under continuous MRI imaging while being teleoperated by a haptic feedback device from outside the scanning room.
  • The developed needle driver prototype was designed and tested for both tumor targeting capability as well as RFA.
  • Experiments were performed to demonstrate MRI-compatibility and position control accuracy with hydraulic actuation, along with an experiment to determine the PHANToM's ability to guide the RFA tool to a tumor nodule within a phantom breast tissue model while continuously imaging within the MRI and receiving force feedback from the RFA tool.
  • CONCLUSION: The teleoperated 1-DOF needle driver system presented in this paper demonstrates the feasibility of implementing a MRI-compatible robot for RFA of breast tumors with haptic feedback capability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hyperthermia. 2005 Sep;21(6):533-46 [16147438.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):120-8 [16425291.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):102-9 [15621997.001]
  • [Cites] IEEE Trans Biomed Eng. 2004 Oct;51(10):1707-16 [15490818.001]
  • [Cites] Radiol Clin North Am. 2004 Sep;42(5):947-62, vii [15337427.001]
  • [Cites] Radiology. 2004 Sep;232(3):835-45 [15333798.001]
  • [Cites] Radiology. 2004 Apr;231(1):215-24 [14990810.001]
  • [Cites] Am Surg. 2003 Jan;69(1):37-40 [12575778.001]
  • [Cites] Clin Radiol. 2001 Jun;56(6):457-65 [11428795.001]
  • [Cites] Cancer J. 2002 Mar-Apr;8(2):177-80 [11999950.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2036-44 [11596017.001]
  • [Cites] Invest Radiol. 2000 Aug;35(8):513-9 [10946979.001]
  • [Cites] Radiology. 2000 Dec;217(3):633-46 [11110923.001]
  • [Cites] Radiology. 2000 Nov;217(2):471-6 [11058648.001]
  • [Cites] Rofo. 2000 Aug;172(8):692-700 [11013611.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1295-303 [17392300.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2006;9(Pt 2):405-12 [17354798.001]
  • [Cites] Med Image Anal. 2007 Feb;11(1):62-78 [17113339.001]
  • [Cites] Magn Reson Imaging. 2007 Jan;25(1):69-77 [17222717.001]
  • [Cites] Oncologist. 2007 Jan;12(1):1-10 [17227896.001]
  • [Cites] J Magn Reson Imaging. 2006 Apr;23(4):578-84 [16508928.001]
  • [Cites] IEEE Trans Biomed Eng. 2005 Feb;52(2):306-13 [15709668.001]
  • (PMID = 19303805.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB008713-01A1; United States / NIBIB NIH HHS / EB / R01 EB008713; United States / NIBIB NIH HHS / EB / R01 EB008713-01A1
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS119227; NLM/ PMC2698937
  •  go-up   go-down


50. Zorcolo L, Fantola G, Cabras F, Marongiu L, D'Alia G, Casula G: Preoperative staging of patients with rectal tumors suitable for transanal endoscopic microsurgery (TEM): comparison of endorectal ultrasound and histopathologic findings. Surg Endosc; 2009 Jun;23(6):1384-9
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging of patients with rectal tumors suitable for transanal endoscopic microsurgery (TEM): comparison of endorectal ultrasound and histopathologic findings.
  • BACKGROUND: Accurate preoperative staging is the key to correct selection of rectal tumors for local excision.
  • TEM was considered the treatment of choice for uT0-1/N0 lesions located between 2 and 12 cm from the anal verge.
  • Mean distance of the tumor from the anal verge was 6.6 cm (range 2-12 cm).
  • CONCLUSIONS: ERUS is useful to confirm the diagnosis of adenoma and predict depth of mural invasion in early rectal cancer.
  • [MeSH-major] Colonoscopy / methods. Endosonography / methods. Microsurgery / methods. Neoplasm Staging / methods. Preoperative Care / methods. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1990 Mar;125(3):385-8 [2306185.001]
  • [Cites] Scand J Gastroenterol Suppl. 2003;(239):34-9 [14743881.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):159-66 [10211490.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 2008 Apr;51(4):379-84; discussion 384 [18236108.001]
  • [Cites] J Surg Oncol. 1997 Apr;64(4):312-7 [9142189.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):770-5 [10378601.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Endoscopy. 1985 Jan;17(1):31-5 [3971938.001]
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):9-20 [10766086.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1557-62 [17114550.001]
  • [Cites] Endoscopy. 1994 Nov;26(9):810-2 [7712998.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):338-45 [10733115.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):328-36 [4007423.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):771-2 [17931167.001]
  • [Cites] Colorectal Dis. 2000 Jan;2(1):13-7 [23577928.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Leber Magen Darm. 1983 Mar;13(2):73-7 [6621245.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):355-64 [12594673.001]
  • [Cites] Radiology. 1991 Apr;179(1):165-70 [2006270.001]
  • [Cites] Int J Colorectal Dis. 2003 May;18(3):222-9 [12673487.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):497-504 [11229667.001]
  • [Cites] Br J Surg. 1994 Jun;81(6):911-4 [8044620.001]
  • [Cites] Dis Colon Rectum. 1993 Feb;36(2):127-34 [8425415.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):457-9 [15048747.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):38-42 [18038181.001]
  • [Cites] Int J Colorectal Dis. 1986 Oct;1(4):203-7 [3298489.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10 Suppl):S10-5 [9378002.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):148-50 [15720352.001]
  • [Cites] Br J Surg. 1988 Oct;75(10 ):1019-22 [3064866.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):10-5 [11786756.001]
  • [Cites] Br J Surg. 2008 Apr;95(4):409-23 [18314929.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):75-80 [10652927.001]
  • [Cites] Radiographics. 2006 May-Jun;26(3):701-14 [16702449.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Radiology. 1999 Apr;211(1):215-22 [10189474.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):541-5 [16508812.001]
  • (PMID = 19263149.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH: Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res; 2008 Nov 15;14(22):7535-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
  • EXPERIMENTAL DESIGN: Patients with solid tumors refractory to standard therapy received i.v. delimotecan as 3-hour infusion once every 6 weeks.
  • The starting dose was 150 mg/m2, followed by an accelerated dose escalation with at least one patient per dose level.
  • Two partial responses were observed in patients with anal cancer (1800 mg/m2) and head and neck cancer (2400 mg/m2).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dextrans / therapeutic use. Neoplasms / drug therapy. Prodrugs / therapeutic use. Topotecan / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010872.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Prodrugs; 0 / T 0128; 7M7YKX2N15 / Topotecan; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


52. Lara-Bohórquez C, González-Cámpora R, Mendoza-García E, Ríos-Martín JJ, Pareja-Megía MJ, López-Beltrán A: TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors. Anal Quant Cytol Histol; 2008 Apr;30(2):105-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors.
  • OBJECTIVE: To identify markers of response to therapy in neuroblastic tumors.
  • STUDY DESIGN: A total of 58 patients with neuroblastic tumor (38 neuroblastomas, 13 ganglioneuroblastomas and 7 ganglioneuromas) were included in the study.
  • TP53, BCL-2, p21Waf1/Cip1 and metallothionein were included as a biologic approach to tumor differentiation, response to therapy and prognosis.
  • RESULTS: Patients who died of disease had the following immunophenotype: BCL-2 (9 of 10), nuclear TP53 (7 of 10) and metallothionein (7 of 10).
  • TP-53 expression was related to clinical stage (p = 0.062) and disease outcome (p = 0.0218).
  • CONCLUSION: TP53, BCL-2, p21Waf1/Cip1 and metallothionein had limited value reflecting tumor maturation (differentiation) or predicting response to therapy.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561747.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


53. Yu JX, Kodibagkar VD, Liu L, Mason RP: A 19F-NMR approach using reporter molecule pairs to assess beta-galactosidase in human xenograft tumors in vivo. NMR Biomed; 2008 Aug;21(7):704-12
Hazardous Substances Data Bank. FLUORINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 19F-NMR approach using reporter molecule pairs to assess beta-galactosidase in human xenograft tumors in vivo.
  • We recently demonstrated the ability to detect beta-galactosidase activity in stably transfected human prostate tumor xenografts in mice in vivo using 19F NMR.
  • Moreover, by using two spectrally resolved reporters (o-fluoro-p-nitrophenyl-beta-D-galactopyranoside and an isomer), two tumors could be interrogated simultaneously revealing lacZ transgene activity in a stably transfected tumor versus no activity in a wild-type tumor.
  • Most significantly, hydrolytic activity observed by 19F NMR corresponded to differential activity in lacZ-expressing tumors.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • [Cites] Nat Biotechnol. 2000 Mar;18(3):321-5 [10700150.001]
  • [Cites] Gene Ther. 2002 Dec;9(23):1564-75 [12424609.001]
  • [Cites] Methods Enzymol. 2000;326:175-202 [11036643.001]
  • [Cites] J Appl Microbiol. 2001 Dec;91(6):1118-30 [11851821.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):546-56 [12217792.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):378-87 [12353253.001]
  • [Cites] Gene Ther. 2003 Mar;10(5):386-95 [12601393.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1796-801 [14583786.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):433-8 [14745516.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1579-83 [14996712.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):616-20 [15004806.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):739-40, 742-3 [1809326.001]
  • [Cites] Biochim Biophys Acta. 1993 Apr 21;1163(1):54-60 [8476929.001]
  • [Cites] Hum Gene Ther. 1998 Aug 10;9(12):1769-74 [9721087.001]
  • [Cites] Magn Reson Imaging. 1999 Jan;17(1):151-5 [9888408.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9821-6 [10449778.001]
  • [Cites] J Mol Biol. 1961 Jun;3:318-56 [13718526.001]
  • [Cites] Bioconjug Chem. 2004 Nov-Dec;15(6):1334-41 [15546200.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):109-17 [15802016.001]
  • [Cites] Nat Med. 2005 Apr;11(4):450-4 [15778721.001]
  • [Cites] Curr Med Chem. 2005;12(7):779-94 [15853711.001]
  • [Cites] Curr Med Chem. 2005;12(7):819-48 [15853714.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41204 [16178628.001]
  • [Cites] Bioorg Med Chem. 2006 Jan 15;14(2):326-33 [16185878.001]
  • [Cites] J Med Chem. 2006 Mar 23;49(6):1991-9 [16539386.001]
  • [Cites] Med Chem. 2005 May;1(3):255-62 [16787321.001]
  • [Cites] Magn Reson Med. 2006 Jul;56(1):51-9 [16724301.001]
  • [Cites] Magn Reson Imaging. 2006 Sep;24(7):959-62 [16916713.001]
  • [Cites] NMR Biomed. 2007 May;20(3):275-90 [17451181.001]
  • [Cites] FASEB J. 2007 Jul;21(9):2014-9 [17351127.001]
  • [Cites] Lett Appl Microbiol. 2000 Apr;30(4):336-40 [10792658.001]
  • (PMID = 18288788.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR002584; United States / NCI NIH HHS / CA / P20 CA 86354; United States / NCI NIH HHS / CA / P20 CA086354; None / None / / U24 CA126608-01; None / None / / P20 CA086354-02; United States / NCRR NIH HHS / RR / P41-RR02584; United States / NCI NIH HHS / CA / CA086354-03; United States / NCI NIH HHS / CA / U24 CA126608; United States / NCI NIH HHS / CA / P20 CA086354-02; United States / NCI NIH HHS / CA / P20 CA086354-03; United States / NCI NIH HHS / CA / U24 CA126608-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-fluoro-4-nitrophenyl galactopyranoside; 28347-45-7 / Nitrophenylgalactosides; 284SYP0193 / Fluorine; EC 3.2.1.23 / beta-Galactosidase
  • [Other-IDs] NLM/ NIHMS263817; NLM/ PMC3044929
  •  go-up   go-down


54. Cunha IW, Carvalho KC, Martins WK, Marques SM, Muto NH, Falzoni R, Rocha RM, Aguiar S, Simoes AC, Fahham L, Neves EJ, Soares FA, Reis LF: Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol; 2010 Feb;3(1):23-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors.
  • Soft tissue tumors represent a group of neoplasia with different histologic and biological presentations varying from benign, locally confined to very aggressive and metastatic tumors.
  • The understanding of these molecular alterations mechanism will be critical to discriminate patients who need systemic treatment from those that can be treated only locally and could also guide the development of new drugs' against this tumors.
  • Using 102 tumor samples representing a large spectrum of these tumors, we performed expression profiling and defined differentially expression genes that are likely to be involved in tumors that are locally aggressive and in tumors with metastatic potential.
  • These genes are mainly related to cell-cell and cell-extracellular matrix interactions and cell proliferation and might represent helpful tools for a more precise classification and diagnosis as well as potential drug targets.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1063-9 [15252314.001]
  • [Cites] Cell Prolif. 2004 Apr;37(2):161-75 [15030550.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7201-4 [15492233.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):611-22 [15548371.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2192-201 [15914641.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):4049-57 [16129888.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):487-98 [16428491.001]
  • [Cites] Liver Int. 2006 May;26(4):424-32 [16629645.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 1;168(1):30-5 [16772118.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):5-24 [16773180.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):447-57 [16981854.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):404-10 [17122636.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Cell Signal. 2007 Jun;19(6):1315-27 [17336041.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13759-68 [17337440.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16401-12 [17412687.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):955-65 [17450526.001]
  • [Cites] Free Radic Biol Med. 2007 Jun 1;42(11):1704-14 [17462538.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):876-84 [17479401.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):885-94 [17479402.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):895-900 [17479403.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3121-32 [17717065.001]
  • [Cites] Semin Thromb Hemost. 2007 Oct;33(7):667-72 [18000793.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1734-43 [18347174.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2814-23 [19109576.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Cytotechnology. 1996;19(3):253-6 [8862015.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1956-66 [9528767.001]
  • [Cites] Oncogene. 1998 Oct 22;17(16):2039-45 [9798675.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):484-5 [11831227.001]
  • [Cites] Circ Res. 2002 Mar 22;90(5):506-8 [11909813.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5859-66 [12384549.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):549-58 [12827608.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):244-51 [14511690.001]
  • [Cites] Clin Exp Metastasis. 2003;20(7):665-74 [14669798.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):235-40 [14685255.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):516-23 [14696115.001]
  • [Cites] Ai Zheng. 2004 Mar;23(3):264-8 [15025954.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8997-9006 [15467746.001]
  • (PMID = 20165692.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2822450
  •  go-up   go-down


55. Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P: Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J; 2010 Mar;24(3):906-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates.
  • On the contrary, DHA exerts anticancer effects, and we have shown that DHA induces apoptosis in neuroblastoma, an embryonal tumor of the sympathetic nervous system.
  • Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Nov;15(5):1011-5 [10536186.001]
  • [Cites] J Lipid Res. 1998 Aug;39(8):1529-42 [9717713.001]
  • [Cites] Neurosci Lett. 2001 Aug 31;309(3):193-6 [11514074.001]
  • [Cites] J Neurochem. 2002 Aug;82(3):655-65 [12153489.001]
  • [Cites] J Exp Med. 2002 Oct 21;196(8):1025-37 [12391014.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):385-92 [12663496.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43807-17 [12923200.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):215-21 [14985462.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):935-45 [15159222.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8491-6 [15152078.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7210-5 [15492235.001]
  • [Cites] J Lipid Res. 1986 Jan;27(1):114-20 [3958609.001]
  • [Cites] Lipids. 1996 Dec;31(12):1283-8 [8972462.001]
  • [Cites] Cancer Biochem Biophys. 1998 Nov;16(4):301-12 [9925279.001]
  • [Cites] Lipids. 2004 Nov;39(11):1125-32 [15726828.001]
  • [Cites] Urol Oncol. 2005 Jan-Feb;23(1):36-48 [15885582.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26600-11 [15894799.001]
  • [Cites] Mol Neurobiol. 2005 Aug;32(1):89-103 [16077186.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2584-93 [16353135.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):842-53 [16523199.001]
  • [Cites] AAPS J. 2006;8(2):E284-97 [16796379.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12499-504 [16888035.001]
  • [Cites] JAMA. 2006 Sep 20;296(11):1371-6 [16985229.001]
  • [Cites] J Lipid Res. 2006 Oct;47(10):2306-13 [16847309.001]
  • [Cites] J Am Soc Mass Spectrom. 2007 Jan;18(1):128-44 [17055291.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):1036-44 [17289900.001]
  • [Cites] J Biol Chem. 2007 Mar 30;282(13):9323-34 [17244615.001]
  • [Cites] Nat Rev Neurosci. 2007 Oct;8(10):743-54 [17882252.001]
  • [Cites] Br J Nutr. 2007 Nov;98(5):873-7 [17688705.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):525-34 [17763971.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):327-35 [18032006.001]
  • [Cites] Annu Rev Pathol. 2008;3:279-312 [18233953.001]
  • [Cites] J Anal Toxicol. 2008 Mar;32(2):183-6 [18334104.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2912-9 [18413760.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):349-61 [18437155.001]
  • [Cites] Chem Phys Lipids. 2008 May;153(1):47-56 [18343223.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3985-91 [18483285.001]
  • [Cites] Nat Rev Neurosci. 2008 Jul;9(7):568-78 [18568016.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(32):5894-955 [18649300.001]
  • [Cites] Apoptosis. 2008 Sep;13(9):1172-83 [18679798.001]
  • [Cites] Subcell Biochem. 2008;49:145-68 [18751911.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):363-77 [18479809.001]
  • [Cites] FASEB J. 2008 Oct;22(10):3525-36 [18591367.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3203-11 [18852124.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):661-74 [18715952.001]
  • [Cites] Clin Nutr. 2008 Oct;27(5):685-93 [18639956.001]
  • [Cites] Nutr Cancer. 2009;61(1):123-30 [19116882.001]
  • [Cites] Apoptosis. 2009 Apr;14(4):424-38 [19259824.001]
  • [Cites] Chemistry. 2009 Oct 12;15(40):10634-40 [19746460.001]
  • [Cites] Cancer Lett. 2000 Mar 13;150(1):101-9 [10755393.001]
  • (PMID = 19890019.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK074448; United States / NIGMS NIH HHS / GM / GM38765; United States / NIDDK NIH HHS / DK / DK074448; United States / NIDCR NIH HHS / DE / P50-DE016191; United States / NIGMS NIH HHS / GM / R01 GM038765; United States / NIDCR NIH HHS / DE / P50 DE016191; United States / NIGMS NIH HHS / GM / R37 GM038765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Lipoxygenase Inhibitors; 25167-62-8 / Docosahexaenoic Acids; 90780-52-2 / 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase
  • [Other-IDs] NLM/ PMC2830131
  •  go-up   go-down


56. Peerbooms JC, Simons JL, Tetteroo GW, De Graaf EJ: Curative resection of rectal carcinoid tumors with transanal endoscopic microsurgery. J Laparoendosc Adv Surg Tech A; 2006 Oct;16(5):435-8
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of rectal carcinoid tumors with transanal endoscopic microsurgery.
  • BACKGROUND: Transanal endoscopic microsurgery is a minimally invasive technique for local resection of rectal tumors.
  • Its place needs to be defined for resection of carcinoid tumors of the rectum.
  • MATERIALS AND METHODS: From 1998 to 2004, rectal carcinoid tumors were diagnosed in 5 patients.
  • The diagnosis was suggested at biopsy in all patients.
  • All tumors were resected full thickness with transanal endoscopic microsurgery.
  • RESULTS: At the time of operation all tumors were small without clinical or biochemical signs of metastasis.
  • All resected tumors were highly differentiated and had free margins without invasion into the submucosa.
  • CONCLUSION: Transanal endoscopic microsurgery is an excellent technique for removal of carcinoid tumors of the rectum and even the distal part of the sigmoid, if the diameter is <1 cm without invasion of the rectal wall.
  • [MeSH-major] Carcinoid Tumor / surgery. Endoscopy, Gastrointestinal / methods. Microsurgery / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Anal Canal. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004864.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Tannapfel A, Wittekind C: [The current TNM system for gastrointestinal tumors part II]. Pathologe; 2010 Sep;31(5):348-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The current TNM system for gastrointestinal tumors part II].
  • [Transliterated title] Aktuelles TNM-System der gastrointestinalen Tumoren Teil II.
  • No changes were made for tumours of the anal canal, the gallbladder (excluding the inclusion of tumours of the cystic duct) and tumours of the pancreas and the ampulla of Vater.
  • [MeSH-major] Digestive System Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Ampulla of Vater / pathology. Appendiceal Neoplasms / classification. Appendiceal Neoplasms / pathology. Carcinoid Tumor / classification. Carcinoid Tumor / pathology. Carcinoma, Hepatocellular / classification. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / classification. Cholangiocarcinoma / pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Common Bile Duct Neoplasms / pathology. Disease Progression. Gallbladder Neoplasms / classification. Gallbladder Neoplasms / pathology. Gastrointestinal Stromal Tumors / classification. Gastrointestinal Stromal Tumors / pathology. Humans. Lymphatic Metastasis / pathology. Mitotic Index. Neoplasm Invasiveness / pathology. Neuroendocrine Tumors / classification. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / classification. Pancreatic Neoplasms / pathology. Prognosis. Rectal Neoplasms / classification. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pathologe. 2010 Sep;31(5):353-4 [20809402.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):477-89 [16625094.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Virchows Arch. 2010 Jun;456(6):595-7 [20422210.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):256-65 [18506737.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • (PMID = 20798945.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Kim MJ, Lee JE, Kim SJ, Kim KH, Kim ES, Cho KB, Park KS: [A case of synchronous colonic laterally spreading tumors treated by sequential endoscopic submucosal dissection performed on two consecutive days]. Korean J Gastroenterol; 2010 Sep;56(3):196-200
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous colonic laterally spreading tumors treated by sequential endoscopic submucosal dissection performed on two consecutive days].
  • Endoscopic submucosal dissection (ESD) is an useful therapeutic technique for large gastrointestinal epithelial tumors that it provides an en bloc resection.
  • Although there is some controversy about the role of ESD for colorectal lesions, for large lesions in the distal rectum, ESD has the advantage of preserving anal function.
  • There is no consensus as to whether ESD is the optimal treatment for synchronous large colorectal laterally spreading tumors (LSTs) that cannot be removed en-bloc by conventional endoscopic mucosal resection.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Dissection. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adenoma, Villous / diagnosis. Colonoscopy. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Male. Middle Aged. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847610.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


59. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL: MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol; 2008 Jun;190(6):1534-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR elastography of liver tumors: preliminary results.
  • OBJECTIVE: The purpose of this study was to evaluate the potential value of MR elastography (MRE) in the characterization of solid liver tumors.
  • MATERIALS AND METHODS: Forty-four liver tumors (14 metastatic lesions, 12 hepatocellular carcinomas, nine hemangiomas, five cholangiocarcinomas, three cases of focal nodular hyperplasia, and one hepatic adenoma) were evaluated with MRE.
  • The tumors were identified on T2- and T1-weighted and gadolinium-enhanced T1-weighted images, and the MRE images were obtained through the tumor.
  • The mean shear stiffness of the tumor was calculated with a manually specified region of interest over the tumor in the stiffness map.
  • The stiffness value of tumor-free hepatic parenchyma was calculated.
  • Statistical analysis was performed on the stiffness values for differentiation of normal liver, fibrotic liver, benign tumors, and malignant tumors.
  • RESULTS: Malignant liver tumors had significantly greater mean shear stiffness than benign tumors (10.1 kPa vs 2.7 kPa, p < 0.001), fibrotic liver (10.1 kPa vs 5.9 kPa, p < 0.001), and normal liver (10.1 kPa vs 2.3 kPa, p < 0.001).
  • Fibrotic livers had stiffness values overlapping both the benign and the malignant tumors.
  • A cutoff value of 5 kPa accurately differentiated malignant tumors from benign tumors and normal liver parenchyma in this preliminary investigation.
  • CONCLUSION: MR elastography is a promising noninvasive technique for assessing solid liver tumors.
  • Use of MRE may lead to new quantitative tissue characterization parameters for differentiating benign and malignant liver tumors.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):63-71 [11436216.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2 [17916548.001]
  • [Cites] Med Image Anal. 2001 Dec;5(4):237-54 [11731304.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):803-11 [12942086.001]
  • [Cites] Med Image Anal. 2003 Dec;7(4):465-73 [14561551.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1854-7 [7569924.001]
  • [Cites] Radiology. 1996 Mar;198(3):920-6 [8628896.001]
  • [Cites] Nat Med. 1996 May;2(5):601-3 [8616724.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] Magn Reson Imaging. 2005 Feb;23(2):159-65 [15833607.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):173-9 [16521091.001]
  • [Cites] Radiology. 2006 Aug;240(2):440-8 [16864671.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Acta Radiol. 2007 Apr;48(3):327-30 [17453505.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S49-60 [17486052.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 18492904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001981-07; United States / NIBIB NIH HHS / EB / R01 EB001981-08; United States / NIBIB NIH HHS / EB / R01 EB001981; United States / NIBIB NIH HHS / EB / EB001981; United States / NIBIB NIH HHS / EB / R01 EB001981-07; United States / NIBIB NIH HHS / EB / EB001981-08
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS196000; NLM/ PMC2894569
  •  go-up   go-down


60. Wilson DF, Lee WM, Makonnen S, Apreleva S, Vinogradov SA: Oxygen pressures in the interstitial space of skeletal muscle and tumors in vivo. Adv Exp Med Biol; 2008;614:53-62
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygen pressures in the interstitial space of skeletal muscle and tumors in vivo.
  • In tumors, the oxygen pressures in the two spaces were similar but with large differences among tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1177-84 [15772057.001]
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1503-10 [15579567.001]
  • [Cites] Org Lett. 2005 Apr 28;7(9):1761-4 [15844900.001]
  • [Cites] Appl Opt. 2005 Sep 1;44(25):5239-48 [16149347.001]
  • [Cites] J Appl Physiol (1985). 2006 Dec;101(6):1648-56 [16888050.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):H1831-40 [10564137.001]
  • [Cites] Respir Physiol. 2001 May;126(1):53-63 [11311310.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):75-85 [12062194.001]
  • [Cites] Methods Enzymol. 2002;352:3-31 [12125356.001]
  • [Cites] Anal Biochem. 2002 Nov 15;310(2):191-8 [12423638.001]
  • [Cites] Adv Exp Med Biol. 2003;530:569-75 [14562753.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):677-86 [15130295.001]
  • [Cites] Microcirculation. 2004 Jun;11(4):317-26 [15280071.001]
  • [Cites] Physiologist. 1971 May;14(2):69-82 [5088084.001]
  • [Cites] Microvasc Res. 1973 May;5(3):254-62 [4709724.001]
  • [Cites] Microvasc Res. 1976 Jul;12(1):59-70 [967026.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5476-82 [3571219.001]
  • [Cites] J Biol Chem. 1988 Feb 25;263(6):2712-8 [2830260.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1649-51 [3420417.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 2):H1676-80 [8184947.001]
  • [Cites] Biophys J. 1994 Nov;67(5):2048-59 [7858142.001]
  • [Cites] Biophys J. 1996 Apr;70(4):1609-17 [8785320.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 2):H2233-40 [9176291.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6590-5 [9618456.001]
  • [Cites] Adv Exp Med Biol. 1998;454:367-74 [9889913.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1717-22 [10206282.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 1):G1515-20 [10362656.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):203-13 [15798296.001]
  • (PMID = 18290314.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS-31465; United States / NINDS NIH HHS / NS / R01 NS031465-14; United States / NHLBI NIH HHS / HL / R01 HL081273-02; United States / NINDS NIH HHS / NS / R01 NS031465; United States / NINDS NIH HHS / NS / NS031465-13A2; United States / NHLBI NIH HHS / HL / R01 HL081273; United States / NHLBI NIH HHS / HL / HL081273-02; United States / NINDS NIH HHS / NS / NS031465-15; United States / NHLBI NIH HHS / HL / R01 HL081273-01A1; United States / NCI NIH HHS / CA / U54 CA105008; United States / NINDS NIH HHS / NS / R01 NS031465-15; United States / NHLBI NIH HHS / HL / HL081273-01A1; United States / NINDS NIH HHS / NS / R01 NS031465-13A2; United States / NCI NIH HHS / CA / U54 CA105008-01; United States / NINDS NIH HHS / NS / NS031465-14; United States / NHLBI NIH HHS / HL / HL081273
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dendrimers; 0 / Metalloporphyrins; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS79505; NLM/ PMC2590629
  •  go-up   go-down


61. Mistrangelo M, Mobiglia A, Cassoni P, Castellano I, Maass J, Martina MC, Bellò M, Mussa A: [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases]. Suppl Tumori; 2005 May-Jun;4(3):S29-30
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases].
  • [Transliterated title] Il carcinoma verrucoso dell'ano o tumore di buschke-lowenstein dell'ano: stadiazione e trattamento presentazione di 3 casi.
  • INTRODUCTION: Giant condyloma acuminatum or Buschke Lowenstein tumor of the anorectal and perianal regions is an uncommon entity that commonly affects genitalia.
  • The hallmark of the disease is the high rate of recurrence (66%) and malignant transformation (56%).
  • MATERIALS AND METHODS: At the Oncological Surgical Department, University of Turin, three patients were diagnosed with a Buschke Lowenstein tumor.
  • In one case we observed a late anal stenosis treated with local dilatations.
  • One patient with a small persistence of the disease was treated with cryotherapy.
  • All inguinal nodes revealed negative to definitive histological exam, that confirmed the diagnosis of Buschke Lowenstein tumor of the primary lesion.
  • CONCLUSIONS: Buschke Lowenstein tumors are rare but extensive lesions difficult to treat.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / surgery. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Buschke Lowenstein Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437884.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


62. Bellutti M, Fry LC, Schmitt J, Seemann M, Klose S, Malfertheiner P, Mönkemüller K: Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci; 2009 May;54(5):1050-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy.
  • BACKGROUND: Neuroendocrine tumors (NET) account for one-third of all small bowel neoplasms.
  • The search for the primary tumor in NET is important, even though it is difficult to localize, as its surgical excision leads to a better prognosis, even in metastasized stages of the disease.
  • The objective of this study was to evaluate the use of double balloon enteroscopy (DBE) for the detection of the primary tumor in patients with NET.
  • METHODS: Twelve consecutive patients (eight women, four men) with suspected carcinoid syndrome, either metastatic to the liver (n=5), symptoms of a neuroendocrine tumor with elevated tumor markers (n=5), or obscure gastrointestinal bleeding (n=2) underwent DBE for the search of the primary tumor or the source of bleeding.
  • The CT scan and sonography of the abdomen as well as EGD and ileocolonoscopy were unable to detect the primary tumor in any patient.
  • A submucosal tumor of the ileum or the jejunum could be detected by DBE was detected in seven patients (58%) (anal route, n=4; oral route, n=3).
  • In four of these patients (33%) this finding could be confirmed by the surgical resection of a NET.
  • In two patients (17%) with a submucosal ileum protrusion suspicious for NET, laparotomy and intraoperative endoscopy did not confirm the tumor.
  • CONCLUSIONS: In this study, the diagnostic yield of DBE for primary tumor search in patients with metastatic or suspected NET was 33%.
  • Although endoscopic small bowel investigation by DBE seems to enrich the diagnostic possibilities for the diagnosis of small bowel-NET, at the present time DBE should only be performed in selected cases, possibly based on a positive previous work-up.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Gastrointestinal Hemorrhage / etiology. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Liver Neoplasms / secondary. Malignant Carcinoid Syndrome / pathology. Neuroendocrine Tumors / pathology

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770038.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; RWM8CCW8GP / Octreotide
  •  go-up   go-down


63. Lee JS, Choi YD, Choi C, Lee MC, Park CS, Min KW: Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth. Anal Quant Cytol Histol; 2005 Aug;27(4):202-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth.
  • OBJECTIVE: To evaluate the expression of tumor suppressor gene phosphatase and tensin homologue on chromosome 10 (PTEN) in ovarian epithelial tumors and its correlation with tumor growth and clinicopathologic features in ovarian adenocarcinomas.
  • STUDY DESIGN: Immunohistochemical staining with anti-PTEN antibody was performed in 54 adenocarcinomas and 23 borderline tumors of the ovary.
  • RESULTS: Reduced PTEN expression was significantly higher among the adenocarcinomas than the borderline tumors (p < 0.001).
  • The Ki-67 index (KI) and apoptotic index were significantly higher in adenocarcinomas as compared with borderline tumors (p < 0.001).
  • Tumors with reduced PTEN expression in ovarian adenocarcinomas had a significantly higher KI than those with normal PTEN expression (p < 0.01).
  • CONCLUSION: Our results suggest that alteration of the PTEN gene may be associated with malignant transformation of ovarian epithelial tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220831.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


64. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-associated tumors].
  • [Transliterated title] HIV-assoziierte Tumore.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • The role of HPV in UV-associated tumors is not yet determined.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1057-61 [8262827.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Eur J Med Res. 1999 Dec 16;4(12 ):507-13 [10611054.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):57-9 [11823698.001]
  • [Cites] AIDS. 2003 Nov 7;17(16):2279-90 [14571179.001]
  • [Cites] Eur J Med Res. 1998 Mar 23;3(3):127-47 [9502754.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1526-30 [15083180.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):147-54 [12115328.001]
  • [Cites] Eur J Med Res. 1999 Dec 16;4(12):514-6 [10611055.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1803-9 [12891066.001]
  • [Cites] Eur J Med Res. 1999 Mar 26;4(3):95-100 [10085275.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] Infection. 2005 Jun;33(3):140-7 [15940415.001]
  • [Cites] Cancer Invest. 2001;19(6):573-80 [11486699.001]
  • [Cites] Acta Oncol. 2000;39(2):207-11 [10859012.001]
  • [Cites] J Interferon Cytokine Res. 2002 Mar;22(3):295-303 [12034036.001]
  • [Cites] Hautarzt. 1991 Aug;42(8):492-8 [1717402.001]
  • [Cites] Dtsch Med Wochenschr. 2003 Sep 19;128(38):1957-62 [14502448.001]
  • [Cites] Eur J Med Res. 2005 Jan 28;10(1):43-5 [15737953.001]
  • (PMID = 17036250.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


65. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Small tumors of the anal margin were not included since they were treated by surgical excision only.
  • Seventy-one patients had no evidence of nodal disease, whereas 30 presented with involved regional nodes.
  • Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy.
  • Lesions greater than 5 cm received an additional boost by interstitial or external radiation depending on circumferential extension of the residual tumor.
  • RESULTS: Overall survival and colostomy-free survival rates for patients with anal canal cancer were 75 percent and 87 percent at five years, respectively.
  • Patients with anal margin cancer had a less favorable outcome with five-year-overall and colostomy-free survival rates of 54 percent and 69 percent, respectively.
  • After correction for imbalance between anal canal and anal margin tumors, i.e., exclusion of T1 tumors of the anal canal, difference in overall survival remained significant (73 percent vs. 54 percent, P = 0.01).
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • Initial tumor response at six weeks (P = 0.03) was predictive for colostomy-free survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


66. Li Y, Tabatabai ZL, Lee TL, Hatakeyama S, Ohyama C, Chan WY, Looijenga LH, Lau YF: The Y-encoded TSPY protein: a significant marker potentially plays a role in the pathogenesis of testicular germ cell tumors. Hum Pathol; 2007 Oct;38(10):1470-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Y-encoded TSPY protein: a significant marker potentially plays a role in the pathogenesis of testicular germ cell tumors.
  • TSPY is expressed at high levels in gonadoblastoma tissues, supporting its possible oncogenic function in this type of germ cell tumors.
  • To explore the possibility that this Y chromosome gene is also involved in pathogenesis of the more common testicular germ cell tumors (TGCTs), we have conducted various expression studies using immunohistochemistry, Western blotting, and reverse transcription-polymerase chain reaction analysis on 171 cases of TGCTs and selected normal testis controls.
  • Our results demonstrated that TSPY protein is abundantly expressed in the precursor, carcinoma in situ or intratubular germ cell neoplasia unclassified, and seminoma, but only minimally or not expressed in various types of nonseminomas.
  • TSPY coexpresses with established germ cell tumor markers (such as placental-like alkaline phosphatase, c-KIT, OCT4) and proliferative markers (such as Ki-67 and cyclin B1) in the same tumor cells at both RNA and protein levels.
  • Our results suggest that TSPY, in combination with other markers, could be an important marker for diagnosis and subclassification of TGCTs and support its role in the pathogenesis of both gonadoblastoma and TGCTs.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Dec;189(4):623-6 [10629567.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Nov;14(3):210-4 [8589038.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):166-86 [11144894.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):67-71 [11173833.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):160-4 [11173850.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2359-64 [11956097.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Oct;24(5):263-79 [12408559.001]
  • [Cites] APMIS. 2003 Jan;111(1):161-71; discussion 172-3 [12752258.001]
  • [Cites] APMIS. 2003 Jan;111(1):267-78; discussion 278-9 [12752272.001]
  • [Cites] Nature. 2003 Jun 19;423(6942):825-37 [12815422.001]
  • [Cites] Hum Mol Genet. 1996 Nov;5(11):1801-7 [8923009.001]
  • [Cites] Histopathology. 1997 Feb;30(2):177-86 [9190360.001]
  • [Cites] APMIS. 1998 Jan;106(1):3-11; discussion 12 [9524557.001]
  • [Cites] APMIS. 1998 Jan;106(1):198-204; discussion 204-6 [9524579.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):921-7 [10090875.001]
  • [Cites] Cancer. 1953 May;6(3):455-63 [13042769.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):108-10 [15689977.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] J Pathol. 2005 Jun;206(2):242-9 [15818593.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):863-8 [15821122.001]
  • [Cites] Am J Med Genet A. 2005 Jun 1;135(2):150-4 [15880570.001]
  • [Cites] Hum Pathol. 2005 May;36(5):512-21 [15948118.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5181-9 [15958562.001]
  • [Cites] Genesis. 2005 Aug;42(4):263-75 [16035036.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5295-303 [15998778.001]
  • [Cites] Cell Cycle. 2005 Aug;4(8):1107-12 [15970669.001]
  • [Cites] Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56 [16168501.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):1856-67 [15958521.001]
  • [Cites] Trends Biochem Sci. 2005 Nov;30(11):630-41 [16236519.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):10875-94 [16314512.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):290-302 [16397242.001]
  • [Cites] J Pathol. 2006 Feb;208(3):395-400 [16273510.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):820-7 [16424014.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Hum Reprod Update. 2006 May-Jun;12(3):303-23 [16540528.001]
  • [Cites] J Pathol. 2006 May;209(1):25-33 [16456896.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2404-13 [16608895.001]
  • [Cites] Genomics. 2006 Jul;88(1):18-33 [16678385.001]
  • [Cites] BMC Cancer. 2006;6:154 [16762081.001]
  • [Cites] Results Probl Cell Differ. 2006;42:271-328 [16903215.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7695-701 [14576833.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Oct-Nov;16(8):1157-63 [14594176.001]
  • [Cites] Cytogenet Genome Res. 2003;101(3-4):250-60 [14684991.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jan;5(1):45-54 [14708009.001]
  • [Cites] Stem Cells. 2004;22(2):169-79 [14990856.001]
  • [Cites] Hum Reprod. 2004 Jun;19(6):1338-44 [15105401.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):93-138 [15172750.001]
  • [Cites] J Pathol. 2004 Jul;203(3):849-57 [15221945.001]
  • [Cites] Cancer. 1970 Jun;25(6):1340-56 [4193741.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Apr;25(2):191-218 [3548944.001]
  • [Cites] Development. 1987;101 Suppl:151-5 [3503713.001]
  • [Cites] Hum Mol Genet. 1992 Dec;1(9):717-26 [1284595.001]
  • [Cites] Am J Hum Genet. 1995 Dec;57(6):1400-7 [8533770.001]
  • [Cites] Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):165-72 [16945824.001]
  • [Cites] Mol Cell Endocrinol. 2006 Sep 26;257-258:35-46 [16904257.001]
  • [Cites] Mol Carcinog. 2000 Apr;27(4):308-21 [10747295.001]
  • (PMID = 17521702.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD038117-05; United States / NICHD NIH HHS / HD / R01 HD038117; United States / NCI NIH HHS / CA / R21 CA152589; United States / BLRD VA / BX / I01 BX000865; United States / NICHD NIH HHS / HD / HD038117-05
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / RNA, Messenger; 0 / TSPY1 protein, human
  • [Other-IDs] NLM/ NIHMS31727; NLM/ PMC2744854
  •  go-up   go-down


67. Tuomela J, Valta M, Seppänen J, Tarkkonen K, Väänänen HK, Härkönen P: Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer; 2009;9:362
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.
  • METHODS: We studied the roles of VEGF-C and VEGFR3 in prostate cancer metastasis by blocking VEGFR3 using intravenous adenovirus-delivered VEGFR3-Ig fusion protein (VEGFR3-Ig) and by ectopic expression of VEGF-C in PC-3 prostate tumors in nude mice.
  • RESULTS: VEGFR3-Ig decreased the density of lymphatic capillaries in orthotopic PC-3 tumors (p < 0.05) and inhibited metastasis to iliac and sacral lymph nodes.
  • In addition, tumor volumes were smaller in the VEGFR3-Ig-treated group compared with the control group (p < 0.05).
  • The size of orthotopic and subcutaneous PC-3/VEGF-C tumors was significantly greater than that of PC-3/mock tumors (both p < 0.001).
  • Interestingly, while most orthotopic PC-3 and PC-3/mock tumors grown for 4 weeks metastasized to prostate-draining lymph nodes, orthotopic PC-3/VEGF-C tumors primarily metastasized to the lungs.
  • PC-3/VEGF-C tumors showed highly angiogenic morphology with an increased density of blood capillaries compared with PC-3/mock tumors (p < 0.001).
  • CONCLUSION: The data suggest that even though VEGF-C/VEGFR3 pathway is primarily required for lymphangiogenesis and lymphatic metastasis, an increased level of VEGF-C can also stimulate angiogenesis, which is associated with growth of orthotopic prostate tumors and a switch from a primary pattern of lymph node metastasis to an increased proportion of metastases at distant sites.
  • [MeSH-major] Cell Proliferation. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / pathology. Vascular Endothelial Growth Factor C / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Lymphangiogenesis. Lymphatic Metastasis. Male. Mice. Mice, Nude. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):819-25 [12048269.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8868-73 [12070340.001]
  • [Cites] FASEB J. 2002 Jul;16(9):922-34 [12087053.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] J Urol. 2003 Mar;169(3):849-54 [12576797.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):167-77 [12883995.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):193-9 [14716745.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):3-12 [14984763.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4400-4 [15231646.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5137-44 [15297417.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):909-15 [15474514.001]
  • [Cites] Cancer Res. 1975 Dec;35(12):3698-704 [1192428.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):977-81 [10551327.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2406-12 [10590384.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1786-90 [11280723.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4762-73 [11532940.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):893-903 [11549582.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):946-51 [11948478.001]
  • [Cites] Urology. 1983 Apr;21(4):337-44 [6340324.001]
  • [Cites] J Urol. 1983 Aug;130(2):290-2 [6876275.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 17;84(12):951-7 [1378502.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1751 [8612600.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3898-911 [9233800.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):309-13 [10390013.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):143-52 [15297858.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):14-21 [15632376.001]
  • [Cites] Cardiovasc Res. 2005 Feb 15;65(3):550-63 [15664381.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93 [15701844.001]
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):125-32 [15868440.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4739-46 [15930292.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6901-9 [16061674.001]
  • [Cites] Prostate. 2005 Oct 1;65(2):110-6 [15880525.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9566-75 [17018613.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s [17062708.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):593-9 [17234768.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1010-7 [17032920.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] BMC Cancer. 2008;8:81 [18371232.001]
  • [Cites] Nature. 2008 Jul 31;454(7204):656-60 [18594512.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):769-84 [19415685.001]
  • (PMID = 19821979.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC2767356
  •  go-up   go-down


68. Zoonens M, Reshetnyak YK, Engelman DM: Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors. Biophys J; 2008 Jul;95(1):225-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors.
  • The pH-dependent insertion of pHLIP across membranes is proving to be a useful property for targeting acidic tissues or tumors and delivering drugs attached to its C-terminus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biophys J. 1995 Nov;69(5):1999-2010 [8580343.001]
  • [Cites] Biophys J. 1995 Jun;68(6):2361-9 [7647240.001]
  • [Cites] Biophys J. 1996 Nov;71(5):2669-79 [8913604.001]
  • [Cites] Biophys J. 1997 Aug;73(2):831-8 [9251799.001]
  • [Cites] Biochemistry. 1997 Dec 9;36(49):15177-92 [9398245.001]
  • [Cites] Biophys J. 2005 Apr;88(4):2626-37 [15665131.001]
  • [Cites] Curr Opin Struct Biol. 2005 Aug;15(4):378-86 [16043344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6460-5 [16608910.001]
  • [Cites] Cell Mol Biol Lett. 2006;11(1):90-101 [16847752.001]
  • [Cites] Biochim Biophys Acta. 2007 Feb;1768(2):354-65 [17173856.001]
  • [Cites] Biochemistry. 2007 Mar 27;46(12):3888-95 [17338552.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):7893-8 [17483464.001]
  • [Cites] Biophys J. 2007 Oct 1;93(7):2363-72 [17557792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15340-5 [18829441.001]
  • [Cites] Biophys J. 1981 Oct;36(1):1-19 [7284547.001]
  • [Cites] Biochemistry. 1981 Dec 22;20(26):7333-8 [7326228.001]
  • [Cites] Biochemistry. 2000 Apr 18;39(15):4432-42 [10757993.001]
  • [Cites] Curr Opin Struct Biol. 2000 Aug;10(4):474-80 [10981638.001]
  • [Cites] Annu Rev Biochem. 2000;69:881-922 [10966478.001]
  • [Cites] Biochemistry. 2002 Oct 8;41(40):12171-8 [12356318.001]
  • [Cites] Biophys J. 2002 Dec;83(6):3324-35 [12496100.001]
  • [Cites] FEBS Lett. 2003 Nov 27;555(1):122-5 [14630331.001]
  • [Cites] FEBS Lett. 2003 Nov 27;555(1):134-8 [14630333.001]
  • [Cites] Biochemistry. 2004 May 18;43(19):5782-91 [15134452.001]
  • [Cites] Biochim Biophys Acta. 1976 Dec 2;455(2):576-87 [999929.001]
  • [Cites] Anal Biochem. 1980 May 1;104(1):10-4 [6892980.001]
  • [Cites] J Mol Biol. 1983 May 15;166(2):211-7 [6854644.001]
  • [Cites] Biochemistry. 1987 Jan 13;26(1):39-45 [3030403.001]
  • [Cites] Biochemistry. 1987 Mar 24;26(6):1783-8 [3593689.001]
  • [Cites] Biophys J. 1989 Feb;55(2):315-25 [2713445.001]
  • [Cites] Biochemistry. 1990 May 1;29(17):4031-7 [1694455.001]
  • [Cites] Biochemistry. 1991 Jul 16;30(28):6997-7008 [2069956.001]
  • [Cites] Biophys J. 1992 Feb;61(2):428-33 [1547330.001]
  • [Cites] Chem Phys Lipids. 1993 Sep;64(1-3):117-27 [8242830.001]
  • [Cites] Biochim Biophys Acta. 1995 May 4;1235(2):452-60 [7756355.001]
  • [Cites] Biochemistry. 1996 Apr 23;35(16):5109-24 [8611495.001]
  • (PMID = 18359793.001).
  • [ISSN] 1542-0086
  • [Journal-full-title] Biophysical journal
  • [ISO-abbreviation] Biophys. J.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM070895; United States / NIGMS NIH HHS / GM / R01 GM073857; United States / NIGMS NIH HHS / GM / GM070895; United States / NIGMS NIH HHS / GM / GM073857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Lipid Bilayers; 0 / Peptides
  • [Other-IDs] NLM/ PMC2426637
  •  go-up   go-down


69. Jennewein M, Lewis MA, Zhao D, Tsyganov E, Slavine N, He J, Watkins L, Kodibagkar VD, O'Kelly S, Kulkarni P, Antich PP, Hermanne A, Rösch F, Mason RP, Thorpe PE: Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res; 2008 Mar 1;14(5):1377-85
Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine.
  • PURPOSE: We recently reported that anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of vascular endothelial cells in tumors, probably in response to oxidative stresses present in the tumor microenvironment.
  • In the present study, we tested the hypothesis that a chimeric monoclonal antibody that binds phosphatidylserine could be labeled with radioactive arsenic isotopes and used for molecular imaging of solid tumors in rats.
  • The radiolabeled antibodies were tested for the ability to image subcutaneous Dunning prostate R3227-AT1 tumors in rats.
  • RESULTS: Clear images of the tumors were obtained using planar gamma-scintigraphy and positron emission tomography.
  • Biodistribution studies confirmed the specific localization of bavituximab to the tumors.
  • The tumor-to-liver ratio 72 h after injection was 22 for bavituximab compared with 1.5 for an isotype-matched control chimeric antibody of irrelevant specificity.
  • Immunohistochemical studies showed that the bavituximab was labeling the tumor vascular endothelium.
  • CONCLUSIONS: These results show that radioarsenic-labeled bavituximab has potential as a new tool for imaging the vasculature of solid tumors.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Jul;2(7):399-406 [10878804.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6603-6 [9506954.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6132-40 [12414638.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1479-84 [12459374.001]
  • [Cites] Annu Rev Physiol. 2003;65:701-34 [12471163.001]
  • [Cites] Nat Rev Drug Discov. 2003 Feb;2(2):123-31 [12563303.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Neoplasia. 2003 Jul-Aug;5(4):308-18 [14511402.001]
  • [Cites] J Cell Biochem. 2003 Oct 15;90(3):473-83 [14523981.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):953-60 [15122677.001]
  • [Cites] Methods Enzymol. 2004;385:3-19 [15130730.001]
  • [Cites] Phys Med Biol. 1970 Jul;15(3):517-28 [5485462.001]
  • [Cites] Anal Biochem. 1983 Jul 1;132(1):68-73 [6353995.001]
  • [Cites] Biochim Biophys Acta. 1983 Dec 7;736(1):57-66 [6418205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3751-5 [6587389.001]
  • [Cites] Biochim Biophys Acta. 1987 Nov 13;904(2):268-82 [3117114.001]
  • [Cites] Clin Immunol Immunopathol. 1993 Mar;66(3):193-200 [8432044.001]
  • [Cites] Magn Reson Imaging. 1993;11(7):1007-17 [8231664.001]
  • [Cites] In Vivo. 1993 Nov-Dec;7(6B):581-4 [8193279.001]
  • [Cites] Mol Membr Biol. 1994 Jul-Sep;11(3):181-7 [7742883.001]
  • [Cites] Semin Nucl Med. 1995 Apr;25(2):144-64 [7597418.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):385-91 [8892464.001]
  • [Cites] Ann Thorac Surg. 1996 Dec;62(6):1868-75 [8957415.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2429-42 [9116287.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4646-53 [9788617.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1551-62 [15746060.001]
  • [Cites] Curr Med Chem. 2005;12(7):807-18 [15853713.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4408-16 [15899833.001]
  • [Cites] Appl Radiat Isot. 2005 Sep;63(3):343-51 [15955705.001]
  • [Cites] Neoplasia. 2005 Jul;7(7):678-87 [16026647.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2639-43 [16353142.001]
  • [Cites] J Biol Chem. 2006 Oct 6;281(40):29863-71 [16905548.001]
  • [Cites] Anticancer Agents Med Chem. 2007 May;7(3):335-43 [17504159.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5211-8 [17785577.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3145-50 [11306500.001]
  • (PMID = 18316558.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA086334; United States / NCRR NIH HHS / RR / P41-RR02584; United States / NCI NIH HHS / CA / CA70907; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U24 CA126608
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Phosphatidylserines; 0 / Radioisotopes; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ NIHMS381612; NLM/ PMC3436070
  •  go-up   go-down


70. Searles Nielsen S, Mueller BA, De Roos AJ, Viernes HM, Farin FM, Checkoway H: Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1). Environ Health Perspect; 2005 Jul;113(7):909-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1).
  • Prior research suggests that childhood brain tumors (CBTs) may be associated with exposure to pesticides.
  • The risk of CBT was nonsignificantly increased in relation to the inefficient PON1 promoter allele [per PON1(-108T) allele, relative to PON1(-108CC): odds ratio (OR) = 1.4; 95% confidence interval (CI), 1.0-2.2; p-value for trend = 0.07].
  • Notably, this association was strongest and statistically significant among children whose mothers reported chemical treatment of the home for pests during pregnancy or childhood (per PON1(-108T) allele: among exposed, OR = 2.6; 95% CI, 1.2-5.5; among unexposed, OR = 0.9; 95% CI, 0.5-1.6) and for primitive neuroectodermal tumors (per PON1(-108T) allele: OR = 2.4; 95% CI, 1.1-5.4).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORPYRIFOS .
  • Hazardous Substances Data Bank. DIAZINON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2005 May 15;63(3):240-51 [15538743.001]
  • [Cites] Biochem Pharmacol. 2005 Feb 15;69(4):541-50 [15670573.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] Brain Res. 2001 Feb 9;891(1-2):54-68 [11164809.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Am J Hum Genet. 2001 Jun;68(6):1428-36 [11335891.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):865-74 [11714115.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Feb 28;133(2):151-61 [11882345.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):477-81 [12139735.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1329-33 [12171796.001]
  • [Cites] Paediatr Perinat Epidemiol. 2003 Apr;17(2):201-11 [12675788.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2003 Mar;13(2):100-11 [12679790.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):643-9 [12639220.001]
  • [Cites] Pharmacogenetics. 2003 Jun;13(6):357-64 [12777966.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):812-8 [12783936.001]
  • [Cites] Environ Health Perspect. 2003 Aug;111(11):1403-9 [12928148.001]
  • [Cites] Nat Struct Mol Biol. 2004 May;11(5):412-9 [15098021.001]
  • [Cites] Haematologica. 2004 May;89(5):628-9 [15136237.001]
  • [Cites] Arch Environ Contam Toxicol. 1993 Jan;24(1):87-92 [8466294.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):197-204 [8019366.001]
  • [Cites] Int J Cancer. 1996 Jan 3;65(1):39-50 [8543394.001]
  • [Cites] Am J Epidemiol. 1996 Jan 15;143(2):120-8 [8546112.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):471-4 [8755936.001]
  • [Cites] Environ Health Perspect. 1997 Nov;105(11):1214-20 [9370522.001]
  • [Cites] Brain Res Bull. 1998;45(2):143-7 [9443830.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):797-802 [9752988.001]
  • [Cites] Environ Health Perspect. 1999 Jun;107(6):501-5 [10339452.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):516-21 [10669651.001]
  • (PMID = 16002382.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1 R03 CA106011; United States / NCI NIH HHS / CN / N01-CN-05230; United States / NIEHS NIH HHS / ES / P30ES07033; United States / NIEHS NIH HHS / ES / T32ES07262
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insecticides; EC 3.1.8.1 / Aryldialkylphosphatase; JCS58I644W / Chlorpyrifos; YUS1M1Q929 / Diazinon
  • [Other-IDs] NLM/ PMC1257655
  •  go-up   go-down


71. Zucchini C, Concu M, Martini F, Morelli C, Salfi N, Carinci P, Tognon M, Caramelli E: FHIT oncosuppressor gene expression profile in human anal cancers. Int J Biol Markers; 2007 Jan-Mar;22(1):39-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FHIT oncosuppressor gene expression profile in human anal cancers.
  • The FHIT gene, a member of the histidine triad gene family, is a tumor suppressor gene exhibiting deletions in the majority of human cancers.
  • Little is known about the molecular mechanisms involved in malignant transformation of the lining cells of the anus.
  • FHIT expression was comparatively analyzed at the mRNA level, by RT-PCR, in squamous anal cancers, normal anal tissue and peripheral blood samples. cDNA analyses showed variability in FHIT transcripts, without apparent effects on the predicted amino acid sequence.
  • Our data indicate that the FHIT mRNA detected in anal cancers and in normal samples is heterogeneous.
  • Immunohistochemical data suggest that the Fhit protein is expressed only in a fraction of the tumor cells, while it is strongly expressed in the epithelial cells of glands of the normal anal mucosa.
  • The absence or poor expression of the Fhit protein in anal cancers suggests a role for this tumor suppressor gene product, as a risk factor, in the onset of this human cancer, as reported before for other human gastrointestinal tumors.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Anus Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393360.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


72. Mikropoulos C, Williams T, Munthali L, Summers J: A rare case of anal tumor: Anal carcinosarcoma. World J Gastrointest Oncol; 2010 Dec 15;2(12):446-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of anal tumor: Anal carcinosarcoma.
  • Sarcomatoid carcinoma is a rare tumor with a poor prognosis, otherwise known as carcinosarcoma.
  • Gastrointestinal origin is very rare and only a limited number of anal carcinosarcomas have been reported in the literature.
  • The aim of this case report was to confirm that by combining treatment modalities we can achieve long disease free intervals.
  • Concomitant chemoradiotherapy led to a good partial response and this was followed by a consolidation surgical endo-anal excision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1481-4 [16552827.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):748-9 [12753163.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1611-4 [11149014.001]
  • [Cites] Turk J Gastroenterol. 2006 Sep;17(3):236-9 [16941264.001]
  • [Cites] Histopathology. 1985 Sep;9(9):987-94 [2415439.001]
  • [Cites] Int Surg. 1979 Jan-Feb;64(1):13-9 [536139.001]
  • [Cites] Pathology. 2006 Jun;38(3):264-7 [16753754.001]
  • [Cites] Singapore Med J. 2008 Oct;49(10):e283-5 [18946600.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):118-27 [8367621.001]
  • (PMID = 21191539.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3011099
  • [Keywords] NOTNLM ; Anal tumour / Carcinosarcoma / Chemoradiotherapy / Endo-anal excision / Spindle cell
  •  go-up   go-down


73. Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, Domanski HA, Mandahl N, Liestøl K, Smeland S, Danielsen HE, Mertens F, Lothe RA: Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol; 2009 Oct;11(5):514-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.
  • The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery.
  • For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002).
  • Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Blotting, Western. Comparative Genomic Hybridization. Disease-Free Survival. Female. Gene Expression. Humans. Image Processing, Computer-Assisted / methods. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Software. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Monogr Pathol. 1996;38:129-61 [8744276.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):13-25 [11145248.001]
  • [Cites] Lab Invest. 2001 Jun;81(6):833-44 [11406645.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):908-13 [11453810.001]
  • [Cites] J Clin Pathol. 2001 Aug;54(8):631-6 [11477120.001]
  • [Cites] Histopathology. 2001 Aug;39(2):187-97 [11493336.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):610-5 [12070601.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 15;136(2):113-20 [12237234.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1337-45 [14508395.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cancer. 1994 May 15;73(10):2499-505 [8174045.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):282-8 [8816583.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1443-9 [9414187.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):612-7 [9688181.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Pediatr Dev Pathol. 1999 Jul-Aug;2(4):377-84 [10347283.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):151-60 [10469453.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] Histopathology. 2006 Jan;48(1):42-50 [16359536.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):97-102 [16540739.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):524-32 [16554732.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):187-92 [17111191.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):463-6 [17327286.001]
  • [Cites] Neoplasia. 2007 Aug;9(8):671-7 [17786186.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1855-60 [10595915.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1879-84 [10595918.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):250-5 [7522538.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):65-73 [7815081.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):793-8 [7790113.001]
  • [Cites] Virchows Arch. 1995;427(1):19-26 [7551341.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):202-6 [11135438.001]
  • (PMID = 19182148.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2765341
  •  go-up   go-down


74. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC: Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol; 2008 Mar;61(3):423-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
  • Due to the preclinical synergistic effects seen with topoisomerase I inhibitors and non-overlapping toxicity, UCN-01 and irinotecan were combined in a dose-finding study designed to determine the maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics (PK) of UCN-01 and irinotecan.
  • No objective responses were documented, and four patients had stable disease for at least ten cycles.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):275-80 [10629089.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5600-5 [10681541.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 May;278(5):F792-8 [10807591.001]
  • [Cites] Invest New Drugs. 2000 May;18(2):95-107 [10857990.001]
  • [Cites] J Physiol. 2001 Mar 15;531(Pt 3):585-95 [11251042.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2319-33 [11304786.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3122-9 [12118026.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1247-9 [12189228.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5743-8 [12384533.001]
  • [Cites] Pflugers Arch. 2003 Apr;446(1):52-60 [12690463.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28644-50 [12766174.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):255-62 [12892559.001]
  • [Cites] Eur J Pharmacol. 2004 Feb 6;485(1-3):141-4 [14757134.001]
  • [Cites] Anal Biochem. 2004 May 1;328(1):84-6 [15081912.001]
  • [Cites] Proc Nutr Soc. 2004 May;63(2):251-8 [15294039.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5242-52 [15297428.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6635-44 [15374978.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6840-6 [15501960.001]
  • [Cites] Comput Programs Biomed. 1979 Mar;9(2):115-34 [761456.001]
  • [Cites] J Antibiot (Tokyo). 1987 Dec;40(12):1782-4 [3429345.001]
  • [Cites] J Antibiot (Tokyo). 1989 Apr;42(4):571-6 [2656615.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2081-6 [7683251.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33(4):273-80 [7506638.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 27;219(3):778-83 [8645257.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):763-8 [9398059.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3248-53 [9699650.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42 Suppl:S54-9 [9750030.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):9-20 [10222418.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):664-71 [15701854.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7800-6 [16278402.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40642-9 [16216880.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):334-40 [16284058.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3408-15 [16740765.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4092-9 [16943527.001]
  • (PMID = 17429623.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA 70095
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; 7BU5H4V94A / 7-hydroxystaurosporine; H88EPA0A3N / Staurosporine; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS433906; NLM/ PMC3557498
  •  go-up   go-down


75. Białek A, Tokarz A, Dudek A, Kazimierska W, Bielecki W: Influence of diet enriched with conjugated linoleic acids on their distribution in tissues of rats with DMBA induced tumors. Lipids Health Dis; 2010;9:126
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of diet enriched with conjugated linoleic acids on their distribution in tissues of rats with DMBA induced tumors.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Fatty Acids / metabolism. Linoleic Acids, Conjugated / metabolism. Linoleic Acids, Conjugated / pharmacology. Mammary Neoplasms, Experimental / chemically induced. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / metabolism

  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dairy Sci. 2002 Feb;85(2):295-350 [11913692.001]
  • [Cites] J Anim Physiol Anim Nutr (Berl). 2005 Feb;89(1-2):45-54 [19112715.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 17;1637(3):193-9 [12697300.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):134-8 [12788078.001]
  • [Cites] Cancer Lett. 2003 Jul 10;196(2):161-8 [12860274.001]
  • [Cites] J Nutr. 2000 Dec;130(12):2943-8 [11110851.001]
  • [Cites] J Lipid Res. 2001 Jul;42(7):1056-61 [11441132.001]
  • [Cites] J Lipid Res. 2004 Apr;45(4):736-41 [14754909.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):1118-25 [15159244.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Anal Bioanal Chem. 2005 Mar;381(6):1138-44 [15761741.001]
  • [Cites] J Nutr. 2005 Apr;135(4):778-84 [15795434.001]
  • [Cites] Biochim Biophys Acta. 2005 Jun 1;1734(3):269-76 [15919237.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4):236-40 [15961678.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H652-9 [15778275.001]
  • [Cites] J Nutr. 2005 Aug;135(8):1934-9 [16046719.001]
  • [Cites] Mol Nutr Food Res. 2005 Aug;49(8):756-62 [15995985.001]
  • [Cites] J Nutr. 2006 May;136(5):1305-10 [16614421.001]
  • [Cites] J Chromatogr A. 2007 Jul 20;1157(1-2):422-9 [17532324.001]
  • [Cites] J Nutr. 2007 Dec;137(12):2599-607 [18029471.001]
  • [Cites] BMC Cancer. 2008;8:208 [18652667.001]
  • [Cites] Lipids Health Dis. 2008;7:34 [18826588.001]
  • [Cites] Nutr Cancer. 2002;43(1):52-8 [12467135.001]
  • (PMID = 21044306.001).
  • [ISSN] 1476-511X
  • [Journal-full-title] Lipids in health and disease
  • [ISO-abbreviation] Lipids Health Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Linoleic Acids, Conjugated; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC2988787
  •  go-up   go-down


76. Miyajima K, Takekoshi S, Itoh J, Kakimoto K, Miyakoshi T, Osamura RY: Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors. Acta Histochem Cytochem; 2010 May 1;43(2):33-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.
  • Estrogen-induced pituitary prolactin-producing tumors (PRLoma) in F344 rats express a high level of vascular endothelial growth factor (VEGF) associated with marked angiogenesis and angiectasis.
  • To investigate whether tumor development in E2-induced PRLoma is inhibited by anti-VEGF monoclonal antibody (G6-31), we evaluated tumor growth and observed the vascular structures.
  • These inhibitory effects due to anti-VEGF antibody might be related to the autocrine/paracrine action of VEGF on the tumor cells, because VEGF and its receptor are co-expressed on the tumor cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4238-44 [12213878.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):755-61 [1377162.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):246-53 [2825969.001]
  • [Cites] Br J Neurosurg. 1987;1(2):243-50 [3267288.001]
  • [Cites] Acta Pathol Jpn. 1986 Aug;36(8):1131-7 [3776530.001]
  • [Cites] Endocrinology. 1987 Feb;120(2):617-21 [3803294.001]
  • [Cites] J Exp Med. 1971 Feb 1;133(2):275-88 [4332371.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] Anal Biochem. 1983 Jul 15;132(2):334-7 [6414333.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(14):4549-53 [6589610.001]
  • [Cites] Am J Pathol. 1983 Nov;113(2):198-206 [6638150.001]
  • [Cites] Neuroendocrinology. 1983 Jul;37(1):23-31 [6888657.001]
  • [Cites] Microvasc Res. 1993 Sep;46(2):135-42 [7504160.001]
  • [Cites] Br J Neurosurg. 1995;9(3):331-46 [7546355.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26988-95 [7929439.001]
  • [Cites] Mol Med. 1995 Jan;1(2):120-2 [8529090.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1615-20 [8603410.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Histochem Cytochem. 1997 Jun;45(6):805-13 [9199666.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1155-61 [9214597.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):253-60 [10639567.001]
  • [Cites] Cytobios. 2000;101(398):151-9 [10755214.001]
  • [Cites] J Endocrinol. 2000 May;165(2):483-92 [10810312.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3183-90 [10866309.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):367-80 [10909429.001]
  • [Cites] Recent Prog Horm Res. 2000;55:15-35; discussion 35-6 [11036931.001]
  • [Cites] Curr Opin Biotechnol. 2000 Dec;11(6):617-24 [11102799.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):364-70 [11759065.001]
  • [Cites] Eur J Endocrinol. 2002 Feb;146(2):143-51 [11834422.001]
  • [Cites] J Histochem Cytochem. 2002 Apr;50(4):533-40 [11897806.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4403-9 [12960047.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2004 Jan;112(1):18-23 [14758567.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):131-9 [15299199.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):413-30 [15563306.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6625-31 [16373345.001]
  • [Cites] Life Sci. 2006 Sep 27;79(18):1741-8 [16846617.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):143-53 [17159247.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):335-41 [17235567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10625-30 [17553957.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):249-58 [18172277.001]
  • [Cites] Acta Histochem Cytochem. 2008 Jun 27;41(3):47-57 [18636109.001]
  • [Cites] Acta Histochem Cytochem. 2009 Aug 29;42(4):95-104 [19759870.001]
  • (PMID = 20514290.001).
  • [ISSN] 1347-5800
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2875861
  • [Keywords] NOTNLM ; VEGF / angiogenesis / anti-VEGF antibody / estrogen / prolactinoma
  •  go-up   go-down


77. Kelly LS, Birken S, Puett D: Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance. Mol Cell Endocrinol; 2007 Jan 2;260-262:33-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance.
  • The ability to reliably detect aberrant glycosylation of human chorionic gonadotropin (hCG) may have profound implications for the diagnosis and monitoring of malignant gestational trophoblastic neoplasia, germ cell tumors, other malignancies, and pregnancy complications.
  • Towards this end, we have developed a lectin-based sandwich-type immunoassay to compare the glycosylation patterns of hCG among urine specimens from patients presenting with a normal pregnancy, invasive mole, choriocarcinoma, and male germ cell tumors using carbohydrate-free antibody fragments as capture reagents and a panel of eight lectins, five recognizing neutral sugars and three recognizing sialic acid.
  • Three lectins, however, exhibited differential binding to urinary hCG derived from these normal pregnant controls and that from patients with malignant forms of gestational trophoblastic disease and male germ cell tumors.
  • Galanthus nivalis agglutinin and Maackia amurensis lectin, which bind terminal mannose and alpha(2-3)sialic acid, respectively, preferentially bound pregnancy-derived hCG, whereas the lectin, wheat germ agglutinin, which binds sialic acid and beta(1-4)N-acetylglucosamine, exhibited decreased binding to pregnancy-derived hCG compared to that from patients with male germ cell tumors and malignant gestational trophoblastic neoplasia.
  • The experimental paradigm also holds promise for the development of comparable assays for other glycosylated tumor markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1356-60 [3342414.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1361-6 [2449279.001]
  • [Cites] Jpn J Cancer Res. 1988 Feb;79(2):160-4 [3130349.001]
  • [Cites] Endocrinology. 1988 Jul;123(1):572-83 [2454811.001]
  • [Cites] Biochimie. 1988 Nov;70(11):1575-85 [2853976.001]
  • [Cites] Am J Physiol. 1989 Jun;256(6 Pt 1):E721-4 [2472071.001]
  • [Cites] Endocrinology. 1989 Nov;125(5):2267-72 [2477227.001]
  • [Cites] Obstet Gynecol. 1991 Jan;77(1):53-9 [1984227.001]
  • [Cites] Eur J Cancer. 1991;27(3):277-80 [1851025.001]
  • [Cites] J Endocrinol. 1999 Apr;161(1):99-106 [10194533.001]
  • [Cites] Int J Cancer. 1999 Jun 21;84(3):304-8 [10371351.001]
  • [Cites] Endocrinology. 1992 Apr;130(4):2052-8 [1547728.001]
  • [Cites] J Endocrinol. 1993 Dec;139(3):519-32 [7510772.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1419-23 [7515388.001]
  • [Cites] Tumour Biol. 1994;15(4):230-5 [7939172.001]
  • [Cites] Endocr Rev. 1994 Oct;15(5):650-83 [7843071.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1081-4 [8855978.001]
  • [Cites] Structure. 1996 Nov 15;4(11):1339-52 [8939757.001]
  • [Cites] Prenat Diagn. 1997 Feb;17(2):185-7 [9061770.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):539-44 [9178805.001]
  • [Cites] Tumour Biol. 1997;18(5):274-7 [9276027.001]
  • [Cites] Endocrine. 1997 Aug;7(1):15-32 [9449027.001]
  • [Cites] Prenat Diagn. 1997 Dec;17(12):1188-90 [9467819.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):3-10 [9475142.001]
  • [Cites] Clin Chem. 1999 Dec;45(12):2109-19 [10585342.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):499-508 [10762294.001]
  • [Cites] J Mol Recognit. 2000 Sep-Oct;13(5):223-78 [10992290.001]
  • [Cites] Clin Chem. 2000 Nov;46(11):1796-803 [11067815.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):18-22 [11241305.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):635-43 [11750741.001]
  • [Cites] J Endocrinol. 2002 Mar;172(3):497-506 [11874698.001]
  • [Cites] Prenat Diagn. 2002 Aug;22(8):656-62 [12210572.001]
  • [Cites] Mol Cell Endocrinol. 2002 Aug 30;194(1-2):147-55 [12242037.001]
  • [Cites] Clin Chem. 2003 May;49(5):808-10 [12709375.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):1087-92 [12820352.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jun 30;204(1-2):21-30 [12850278.001]
  • [Cites] Clin Chim Acta. 2004 Mar;341(1-2):199-203 [14967177.001]
  • [Cites] Am J Med. 1979 Sep;67(3):414-20 [474587.001]
  • [Cites] J Clin Endocrinol Metab. 1980 Jun;50(6):1111-20 [7372790.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):654-60 [6305481.001]
  • [Cites] J Biol Chem. 1983 Dec 10;258(23):14126-9 [6643471.001]
  • [Cites] Clin Chim Acta. 1987 Mar 30;163(3):339-49 [3034453.001]
  • [Cites] J Biol Chem. 1988 Jan 15;263(2):728-34 [3335522.001]
  • [Cites] J Biol Chem. 1988 Jan 25;263(3):1157-65 [3335536.001]
  • [Cites] Gynecol Oncol. 1999 Aug;74(2):302-3 [10419751.001]
  • [Cites] Endocrine. 1999 Apr;10(2):137-44 [10451222.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):253-62 [15745745.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):131-41 [15970647.001]
  • (PMID = 17081681.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK033973; United States / NIDDK NIH HHS / DK / DK33973; United States / NIDDK NIH HHS / DK / R01 DK033973-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carbohydrates; 0 / Chorionic Gonadotropin; 0 / Lectins; 0 / glycosylated HCG; GZP2782OP0 / N-Acetylneuraminic Acid
  • [Other-IDs] NLM/ NIHMS14869; NLM/ PMC1847626
  •  go-up   go-down


78. Krand O, Yalti T, Tellioglu G, Kara M, Berber I, Titiz MI: Use of smooth muscle plasty after intersphincteric rectal resection to replace a partially resected internal anal sphincter: long-term follow-up. Dis Colon Rectum; 2009 Nov;52(11):1895-901

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of smooth muscle plasty after intersphincteric rectal resection to replace a partially resected internal anal sphincter: long-term follow-up.
  • PURPOSE: Patients with very low rectal cancer were treated by intersphincteric rectal resection employing partial internal anal sphincter resection.
  • They then underwent smooth muscle plasty to restore internal anal sphincter function.
  • PATIENTS AND METHODS: Patients were selected if their biopsies revealed well-differentiated or moderately well-differentiated very low rectal tumors with distal tumor margins that permitted preservation of part of the internal anal sphincter.
  • RESULTS: Forty-seven patients with T2 to T3 very low rectal carcinomas underwent intersphincteric rectal resection and smooth muscle plasty that extended into the anal canal.
  • The five-year overall and disease-free survival rates were 85% and 82%, respectively.
  • Six months, one year, and two years after intersphincteric rectal resection, 80%, 87%, and 89%, respectively, had good continence (Kirwan I and II).
  • CONCLUSION: Providing neodjuvant treatment and preserving at least half of the functional internal anal sphincter mass produces acceptable oncological and functional outcomes in patients undergoing intersphincteric rectal resection for very low rectal cancer.
  • [MeSH-major] Anal Canal / surgery. Digestive System Surgical Procedures / methods. Muscle, Smooth / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Follow-Up Studies. Humans. Ileostomy. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Surveys and Questionnaires. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966639.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Tomimaru Y, Ohue M, Noura S, Tanida T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1776-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer].
  • A 63-year-old man with a history of anal fistula was admitted to our hospital because the anal pain didn't disappear after the operation.
  • On digital examination, a hard mass measuring 3.0 cm in diameter was found at the anal canal.
  • Colonoscopy revealed another rectal cancer at 15 cm from anal verge.
  • Biopsy of the tumor also showed moderately differentiated adenocarcinoma, resembling the anal canal tumor.
  • Because the histological findings of both tumors were nearly identical, we considered that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal fistula.
  • The patient underwent anterior resection for the rectal cancer, and a local resection for the anal canal cancer.
  • Immunohistochemical staining for Ki-67, p53, Muc2, CD10, CK-7, and CK-20 revealed similar patterns in both tumors.
  • Additionally, genetic analysis for p53, K-ras, and MSI revealed similar patterns in both tumors.
  • We may suggest from these results that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / complications. Rectal Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Seeding


80. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • Of the 69 patients, 66 received radiotherapy (RT) and 3 with in situ disease were treated by local excision alone without RT.
  • Four patients developed local failure outside the initial tumor bed.
  • The 5-year overall survival, colostomy-free survival, and disease-free survival rate was 94%, 85%, and 89%, respectively.
  • CONCLUSION: Most recurrences occurred after a long disease-free interval after treatment and often outside the initial tumor site.
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Gu J, Li J, Yao Y, Lu A, Wang H: Synchronous rectal adenocarcinoma and anal canal adenocarcinoma. Front Med China; 2007 Jul;1(3):333-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous rectal adenocarcinoma and anal canal adenocarcinoma.
  • It is difficult to distinguish a rectal carcinoma with anal metastases from coexistent synchronous anorectal carcinomas.
  • The therapeutic strategy for rectal and anal carcinoma is so different that it should be clearly identified.
  • Five months after resection, he developed an adenocarcinoma in the anal canal.
  • The histological slides of both tumors were reviewed and immunohistochemical studies for cytokeratins (CKs) 7 and 20 were performed.
  • The index tumor demonstrated CK 7-/CK 20+ and the second showed CK7+/CK20+.
  • For this reason, we believe the present case had synchronous adenocarcinomas arising from anal canal and the rectum separately.
  • It is very important to differentiate the anorectal lesions pathologically because of the impact on the therapeutic options available, especially for the lesion arising in the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24573877.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV: Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum; 2009 Feb;52(2):239-47
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia.
  • PURPOSE: High-resolution anoscopy is colposcopy of the anus after applying 3 percent acetic acid.
  • High-resolution anoscopy with biopsy was used as the standard for detecting high-grade anal neoplasia and was compared to detection of high-grade anal neoplasia by anal cytology, human papillomavirus testing, or the combination.
  • A specimen was taken for anal cytology and human papillomavirus testing, followed by high-resolution anoscopy with biopsy of any lesions.
  • RESULTS: Ninety-one percent of HIV-positive and 57 percent of HIV-negative MSM had anal human papillomavirus infection.
  • In HIV-positive men the sensitivity of abnormal cytology to detect high-grade anal neoplasia was 87 percent, and in HIV-negative MSM it was 55 percent.
  • Among HIV-negative men, 9 of 20 cases of high-grade anal neoplasia would have been missed because cytology was negative, but the addition of human papillomavirus positivity increased sensitivity for the combination to 90 percent.
  • CONCLUSIONS: Sensitivity and specificity of anal cytology and human papillomavirus testing are different in HIV-positive and HIV-negative MSM for detecting high-grade anal neoplasia when patients have high-resolution anoscopy-guided biopsy of lesions.
  • High-resolution anoscopy is an effective tool for diagnosing high-grade anal neoplasia.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Endoscopy, Gastrointestinal. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Anus Diseases / diagnosis. Anus Diseases / virology. Biopsy. Cytodiagnosis. HIV Seronegativity. HIV Seropositivity / complications. Homosexuality. Humans. Male. Middle Aged. Polymerase Chain Reaction. Precancerous Conditions / diagnosis. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279418.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NIAID NIH HHS / AI / K23 AI054157; United States / NIAID NIH HHS / AI / R01 CA/AI 88739; United States / NCI NIH HHS / CA / R01 CA54053; United States / NCRR NIH HHS / RR / UL1 RR024131-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Damin DC, Tolfo GC, Rosito MA, Spiro BL, Kliemann LM: Sentinel lymph node in patients with rectal cancer invading the anal canal. Tech Coloproctol; 2010 Jun;14(2):133-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node in patients with rectal cancer invading the anal canal.
  • BACKGROUND: To assess the feasibility of the sentinel lymph node procedure in patients with rectal cancer extending to the anal canal.
  • METHODS: Between January 2005 and April 2008, 15 patients with adenocarcinoma of the rectum with direct invasion of the anal canal and no clinical evidence of inguinal involvement were prospectively enrolled in the study.
  • CONCLUSIONS: The standardized procedure was highly effective in sampling inguinal sentinel nodes in very low rectal cancers, allowing the detection of subclinical metastatic disease.
  • Although this technique can be potentially useful for a subgroup of patients with isolated inguinal metastases, it cannot be routinely recommended for patients with rectal tumors invading the anal canal at this moment.
  • [MeSH-major] Adenocarcinoma / secondary. Anal Canal. Inguinal Canal. Rectal Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Feb;53(1):3-8 [18337684.001]
  • [Cites] Cancer Radiother. 2003 Nov;7 Suppl 1:85s-90s [15124549.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Gastroenterol Clin Biol. 2009 May;33(5):446-50 [19264433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):811-9 [6429097.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):2058-65 [8364884.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):259S-62S [15023764.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1027-9; discussion 1030-1 [12907894.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Colorectal Dis. 2010 Apr;12(4):312-5 [19250258.001]
  • [Cites] Colorectal Dis. 2010 Oct;12(10 Online):e200-5 [19912287.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1464-6 [10566535.001]
  • [Cites] Am J Surg. 1994 Sep;168(3):285-7 [8080070.001]
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):238-42 [2672386.001]
  • [Cites] World J Urol. 2009 Apr;27(2):197-203 [18594830.001]
  • [Cites] Scand J Surg. 2002;91(4):336-8 [12558082.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Br J Clin Pract. 1984 Sep;38(9):324-5 [6477814.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):177-80 [10102348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):741-7 [11597817.001]
  • [Cites] Dis Colon Rectum. 1990 Mar;33(3):212-6 [2311465.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1032-7 [12907896.001]
  • (PMID = 20424879.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


84. Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, Danesi R: Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA J; 2010 Sep;1(3):495-502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluoropyrimidines, including 5-fluorouracil (5-FU), are widely used in the treatment of solid tumors and remain the backbone of many combination regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1994 Dec;24(3):613-4 [7713523.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2248-53 [7964939.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5433-8 [8221682.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):610-5 [8698850.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):325-9 [9516918.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):507-10 [9816197.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):620-6 [10027339.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):768-74 [11895907.001]
  • [Cites] Hum Mutat. 2003 Dec;22(6):498 [14635116.001]
  • [Cites] Genet Med. 2004 Mar-Apr;6(2):102-7 [15017333.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7100-7 [15501990.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):23-44 [15763604.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8699-705 [16361556.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Sep;58(3):396-401 [16421754.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5491-5 [17000684.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5496-502 [17000685.001]
  • [Cites] Clin Pharmacol Ther. 2006 Oct;80(4):384-95 [17015056.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2895-904 [17121937.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]
  • [Cites] C R Biol. 2007 Oct;330(10):764-9 [17905396.001]
  • [Cites] Trends Pharmacol Sci. 2007 Dec;28(12):597-8 [18001850.001]
  • [Cites] PLoS One. 2008;3(12):e4003 [19104657.001]
  • [Cites] Clin Biochem. 2010 Feb;43(3):331-4 [19822137.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):333-8 [9439663.001]
  • [Cites] Genomics. 1998 Aug 1;51(3):391-400 [9721209.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]
  • [Cites] Hum Genet. 1999 Jan;104(1):1-9 [10071185.001]
  • [Cites] Ther Drug Monit. 1999 Apr;21(2):152-4 [10217332.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):307-14 [10410956.001]
  • [Cites] Crit Rev Oncol Hematol. 1999 Mar;30(1):71-9 [10439055.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3032-7 [10955781.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4705-12 [11156223.001]
  • [Cites] Jpn J Cancer Res. 2001 Mar;92(3):337-42 [11267945.001]
  • [Cites] Invest New Drugs. 2001;19(1):41-59 [11291832.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1301-6 [11697844.001]
  • [Cites] Br J Clin Pharmacol. 2002 Jun;53(6):596-603 [12047484.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jul 15;774(2):223-30 [12076692.001]
  • [Cites] Adverse Drug React Toxicol Rev. 2002;21(1-2):1-16 [12140902.001]
  • [Cites] Pharmacogenomics. 2002 Jul;3(4):485-92 [12164772.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):253-8 [12209976.001]
  • [Cites] Ther Drug Monit. 2002 Oct;24(5):588-93 [12352929.001]
  • [Cites] Ann Clin Biochem. 2003 Jan;40(Pt 1):41-5 [12542909.001]
  • [Cites] Eur J Cancer. 2004 May;40(7):939-50 [15093568.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2652-8 [15102667.001]
  • [Cites] J Clin Pharmacol. 2004 Nov;44(11):1260-72 [15496644.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5104-11 [16033824.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5886-92 [16115930.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):79-82 [16761622.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3864; author reply 3864 [16778115.001]
  • [Cites] Clin Biochem. 2007 Jan;40(1-2):11-7 [17046731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1378-83 [17056196.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):271-82 [17064846.001]
  • [Cites] Med Oncol. 2007;24(2):251-8 [17848752.001]
  • [Cites] J Clin Pharm Ther. 2008 Jun;33(3):307-14 [18452418.001]
  • [Cites] JOP. 2009;10(2):215-20 [19287123.001]
  • [Cites] Neoplasma. 2009;56(4):303-16 [19473056.001]
  • (PMID = 23199091.001).
  • [ISSN] 1878-5077
  • [Journal-full-title] The EPMA journal
  • [ISO-abbreviation] EPMA J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3405332
  •  go-up   go-down


85. Rezaul K, Thumar JK, Lundgren DH, Eng JK, Claffey KP, Wilson L, Han DK: Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes Cancer; 2010 Mar;1(3):251-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using highly enriched breast tumor cells, replicate analyses from 3 ERα+ and 3 ERα- human breast tumors resulted in the identification of 2,995 unique proteins with ≥2 peptides.
  • Further, label-free quantitative proteome analysis revealed that 236 proteins were differentially expressed in ERα+ and ERα- breast tumors.
  • Among these, 141 proteins were selectively up-regulated in ERα+, and 95 proteins were selectively up-regulated in ERα- breast tumors.
  • By Gene Ontology molecular function, dehydrogenase, reductase, cytoskeletal proteins, extracellular matrix, hydrolase, and lyase categories were significantly enriched in ERα+, whereas selected calcium-binding protein, membrane traffic protein, and cytoskeletal protein were enriched in ERα- breast tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1999 Apr 1;364(1):122-4 [10087173.001]
  • [Cites] Tumori. 1999 Jan-Feb;85(1):35-40 [10228495.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4440-9 [10442635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11217-22 [10500157.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5379-87 [10681512.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):44-51 [11082274.001]
  • [Cites] Bioinformatics. 2000 Aug;16(8):685-98 [11099255.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):311-7 [11162939.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):36869-72 [11459850.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):431-7 [11485901.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5979-84 [11507038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11462-7 [11562467.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6418-34 [11607842.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(Web Server issue):W317-22 [19465387.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25 [19655166.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2985-90 [6850609.001]
  • [Cites] Cancer Res. 1977 Dec;37(12):4669-71 [922747.001]
  • [Cites] Int J Radiat Biol. 2005 Dec;81(12):937-44 [16524849.001]
  • [Cites] BMC Genomics. 2006;7:127 [16729877.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):65-76 [16799640.001]
  • [Cites] N Engl J Med. 2002 Jan 31;346(5):340-52 [11821512.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Sci STKE. 2002 Jun 25;2002(138):re9 [12084906.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36689-96 [12095985.001]
  • [Cites] EMBO J. 1995 Jun 15;14(12):2827-38 [7796809.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):87-91 [8603051.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):533-7 [9150937.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63 [9192621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1450-4 [9414188.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25770-6 [9748248.001]
  • [Cites] Nucleic Acids Res. 1999 Jan 1;27(1):29-34 [9847135.001]
  • [Cites] Oncogene. 1998 Dec 3;17(22):2863-71 [9879992.001]
  • [Cites] Nat Med. 1999 Feb;5(2):221-5 [9930872.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3965-72 [9814476.001]
  • [Cites] Mol Cell Proteomics. 2005 Feb;4(2):169-81 [15598749.001]
  • [Cites] Chemotherapy. 2007;53(4):233-56 [17595539.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):227-38 [10068081.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Br J Cancer. 1988 Nov;58(5):600-5 [2851309.001]
  • [Cites] Cancer. 1988 Dec 15;62(12):2517-24 [3191451.001]
  • [Cites] J Pathol. 1995 Aug;176(4):343-52 [7562249.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):351-6 [7927940.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Science. 2003 Apr 4;300(5616):142-5 [12677069.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Oct;52(4):319-24 [12783205.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2003 Jul;30(7):457-63 [12823259.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):965-1016 [12843413.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2406-15 [12855612.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45672-9 [12952985.001]
  • [Cites] Physiol Rev. 2003 Oct;83(4):1325-58 [14506307.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Apr;50(1):3-22 [15094156.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):13-25 [15186216.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] BMC Genomics. 2005;6:15 [15710041.001]
  • [Cites] Oncogene. 2005 May 5;24(20):3257-67 [15735728.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24412-9 [15878855.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6218-24 [16194081.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] EMBO J. 2006 Sep 6;25(17):4008-19 [16932749.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2158-64 [16985048.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D247-52 [17130144.001]
  • [Cites] Genome Biol. 2007;8(1):R3 [17204154.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11329-38 [17303558.001]
  • [Cites] Mol Cell Proteomics. 2007 Jun;6(6):1088-102 [17339633.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2552-8 [17363573.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1343-53 [17519225.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):357-64 [17566693.001]
  • [Cites] Mol Cell Proteomics. 2008 Aug;7(8):1420-33 [18426791.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Jun;8(4):243-52 [18537548.001]
  • [Cites] Brief Funct Genomic Proteomic. 2008 Sep;7(5):340-54 [18579614.001]
  • [Cites] Mol Cell Proteomics. 2008 Dec;7(12):2373-85 [18644780.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1544-52 [19286567.001]
  • (PMID = 21779449.001).
  • [ISSN] 1947-6027
  • [Journal-full-title] Genes & cancer
  • [ISO-abbreviation] Genes Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL067569
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3092194
  • [Keywords] NOTNLM ; LC-MS/MS / breast cancer / estrogen receptor / fascin / laser capture microdissection
  •  go-up   go-down


86. Tarakji B, Kujan O, Nassani MZ: Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma. J Cancer Epidemiol; 2010;2010:250606
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Context. Immunohistochemical stains for p53 are used as a diagnostic marker associated with malignancy in several histologic types of salivary gland tumors.
  • This marker may be useful in differentiating pleomorphic adenoma (PA) from carcinoma ex pleomorphic adenoma (CPA), as these tumors are often difficult to distinguish on the basis of morphology alone.
  • Objective. to evaluate whatever inactivation of tumor suppressor gene (p53) increases with the tumor progression from normal salivary tissue to PA and eventually CPA.
  • In all cases of carcinoma ex pleomorphic adenoma, a PA "ghost" was identified, and the malignant element was either undifferentiated carcinoma or adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Jun;182(2):180-4 [9274528.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):265-72 [9648154.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):477-83 [10675478.001]
  • [Cites] Cancer Lett. 1992 Jul 31;65(1):61-71 [1324786.001]
  • [Cites] J Immunol Methods. 1992 Jul 6;151(1-2):237-44 [1378473.001]
  • [Cites] J Pathol. 1992 Apr;166(4):389-94 [1381431.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2008 Sep-Oct;12(5):321-5 [19024217.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):413-22 [8396843.001]
  • [Cites] Br J Cancer. 1996 Mar;73(6):728-34 [8611372.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):224-31 [9917133.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):390-7 [18992915.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):113-21 [6263450.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2037-44 [7697591.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):782-6 [8760010.001]
  • [Cites] J Oral Pathol Med. 1997 May;26(5):217-23 [9178173.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):539-45 [10203588.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Aug;21(4):336-42 [10560511.001]
  • (PMID = 21253477.001).
  • [ISSN] 1687-8566
  • [Journal-full-title] Journal of cancer epidemiology
  • [ISO-abbreviation] J Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3022193
  •  go-up   go-down


87. Giuffrè M, De Sanctis L: Genetic syndrome suspicion: examples of clinical approach in the neonatal unit. Minerva Pediatr; 2010 Jun;62(3 Suppl 1):199-201
MedlinePlus Health Information. consumer health - Genetic Testing.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within this latter group of diseases, a LGA newborn requires a complex differential diagnosis encompassing several syndromes, such as Beckwith-Wiedemman, Sotos, Weaver, Simpson-Golabi-Behmel, Perlman, and Bannayan-Riley-Ruvalcaba.
  • Partial or global overgrowth, other dysmorphisms, abdominal organs anomalies, as well as benign and malignant tumors are the common issues to examine for the diagnosis and the monitoring of all these disorders.
  • [MeSH-major] Early Diagnosis. Genetic Diseases, Inborn / diagnosis. Genetic Testing. Intensive Care Units, Neonatal. Neonatology / methods
  • [MeSH-minor] Abnormalities, Multiple / diagnosis. Abnormalities, Multiple / genetics. Anal Canal / abnormalities. Birth Weight. Congenital Abnormalities / diagnosis. Congenital Abnormalities / genetics. Esophageal Atresia / diagnosis. Esophageal Atresia / epidemiology. Esophageal Atresia / genetics. Esophagus / abnormalities. Fetal Macrosomia / diagnosis. Fetal Macrosomia / etiology. Heart Defects, Congenital / diagnosis. Heart Defects, Congenital / epidemiology. Heart Defects, Congenital / genetics. Hedgehog Proteins / deficiency. Hedgehog Proteins / genetics. Humans. Infant, Newborn. Kidney / abnormalities. Limb Deformities, Congenital / diagnosis. Limb Deformities, Congenital / epidemiology. Limb Deformities, Congenital / genetics. Patient Care Team. Spine / abnormalities. Syndrome. Trachea / abnormalities

  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21089741.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human; VACTERL association
  •  go-up   go-down


88. Chang SS, Smith I, Glazer C, Hennessey P, Califano JA: EIF2C is overexpressed and amplified in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec; 2010;72(6):337-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 12,000 genes) comparing 6 normal tissues and 8 HNSCC tumor tissues.
  • RESULTS: The tumor tissues had an average mRNA expression level of 123 (SD = 49) compared to the normal tissues (18.6, SD = 10) (p = 0.0005) by expression array.
  • Quantitative RT-PCR validation of our expression arrays found that normal tissues had an average expression of 0.76 (SE = 0.08) and tumor tissues of 2.1 (SE = 0.35) (p = 0.0008).
  • CONCLUSION: EIF2C2 is amplified and overexpressed in HNSCC cell lines and primary tumors and functionally significant in cell lines.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • [Cites] Biotechniques. 1993 Sep;15(3):532-4, 536-7 [7692896.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] Laryngoscope. 2006 May;116(5):735-41 [16652080.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Genes Dev. 2007 Aug 15;21(16):1999-2004 [17626790.001]
  • [Cites] Cell Microbiol. 2007 Dec;9(12):2784-94 [17944962.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1437-41 [15284456.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • (PMID = 20924207.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA096784; United States / NIDCD NIH HHS / DC / T32 DC000027; United States / NCI NIH HHS / CA / 5P50CA096784-05; United States / NIDCD NIH HHS / DC / T32DC000027
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Argonaute Proteins; 0 / EIF2C2 protein, human; 0 / Eukaryotic Initiation Factor-2
  • [Other-IDs] NLM/ PMC2975733
  •  go-up   go-down


89. Nieuwenhuis MH, Douma KF, Bleiker EM, Bemelman WA, Aaronson NK, Vasen HF: Female fertility after colorectal surgery for familial adenomatous polyposis: a nationwide cross-sectional study. Ann Surg; 2010 Aug;252(2):341-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies in FAP or colitis patients almost uniformly describe a reduction in fertility after ileal pouch-anal anastomosis, compared with ileorectal anastomosis.
  • Medical data were verified in the FAP-registry of the Netherlands Foundation for the Detection of Hereditary Tumors.
  • The prevalence of fertility problems was similar among those who had undergone ileorectal anastomosis, ileal pouch-anal anastomosis, and proctocolectomy with ileostomy.
  • None of the other surgery-related factors, nor desmoid tumors or cancer were associated significantly with the development of fertility problems.
  • Patients reporting fertility problems were significantly younger at diagnosis of FAP (mean, 20 vs. 27 years, P < 0.05) and at the time of the first surgical procedure (mean, 22 vs. 28 years, P < 0.05).


90. Zoucas E, Frederiksen S, Lydrup ML, Månsson W, Gustafson P, Alberius P: Pelvic exenteration for advanced and recurrent malignancy. World J Surg; 2010 Sep;34(9):2177-84
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Improved surgical techniques and oncological treatment render many advanced pelvic tumors amenable to curative resection.
  • METHODS: From January 2003 to November 2008, 85 patients underwent multivisceral pelvic resection; 87% had colorectal or anal malignancies.
  • Twenty-seven manifested disseminated disease without local recurrence, two developed isolated local recurrence, and six had local and systemic recurrences.
  • [MeSH-major] Anus Neoplasms / surgery. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Pelvic Exenteration
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Length of Stay. Male. Middle Aged. Postoperative Complications / epidemiology. Quality of Life. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2009 Jul;33(7):1502-8 [19421811.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2047-53; discussion 2053-4 [15657653.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):427-35 [9457832.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Surg Today. 2007;37(10):853-9 [17879034.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):700-3 [12828064.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1870-7 [17406945.001]
  • [Cites] Br J Surg. 2009 Feb;96(2):191-6 [19160364.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] World J Urol. 1996;14(2):78-84 [8731122.001]
  • [Cites] Dig Surg. 2003;20(3):192-9; discussion 200 [12759498.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1099-107 [16779712.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4361-7 [12409336.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):610-4 [15196852.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):173-8 [11227932.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):261-8 [16426668.001]
  • [Cites] Eur J Surg Oncol. 2005 Sep;31(7):735-42 [16180267.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):158-66 [12623361.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] Langenbecks Arch Surg. 2009 Jan;394(1):71-7 [18663464.001]
  • [Cites] Oncology. 2000;58(1):31-7 [10644938.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):390-5 [17063304.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1695-1701; discussion 1701-3 [11156453.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6 [8154965.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):680-3 [14766266.001]
  • [Cites] Ann Surg. 2003 Apr;237(4):502-8 [12677146.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1458-61 [16897329.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1438-48 [10566532.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):92-9 [16425312.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):312-9 [10733111.001]
  • [Cites] J Surg Oncol. 2005 Oct 1;92(1):70-5 [16180215.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):127-31 [16598032.001]
  • (PMID = 20512493.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Yeo SG, Kim DY, Kim TH, Kim SY, Chang HJ, Park JW, Choi HS, Oh JH: Local excision following pre-operative chemoradiotherapy-induced downstaging for selected cT3 distal rectal cancer. Jpn J Clin Oncol; 2010 Aug;40(8):754-60
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median tumor size was 3 cm (range, 2-5), and the median distance of the caudal tumor edge from the anal verge was 3 cm (range, 1-4).
  • The pathologic tumor size for three ypT1-2 tumors was 0.9, 1.1 and 2.2 cm.
  • Another patient (ypT2) developed bone metastasis after 8 months and died of the disease.
  • The 5-year local recurrence-free, disease-free and overall survival rates were 90.9%, 81.8% and 88.9%, respectively.
  • [MeSH-major] Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Palliative Care. Premedication. Preoperative Care. Radiotherapy, Adjuvant. Salvage Therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20457724.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • All the patients resumed normal bowel function during 12-24 weeks after operation, with 1-3 times per day.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Irons R, Tsuji PA, Carlson BA, Ouyang P, Yoo MH, Xu XM, Hatfield DL, Gladyshev VN, Davis CD: Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev Res (Phila); 2010 May;3(5):630-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas most (14 of 15) BALB/c mice injected with control cells developed tumors, few (3 of 30) mice injected with Sep15-deficient cells developed tumors (P < 0.0001).
  • Mice injected with the plasmid-transfected control cells had >250 lung metastases per mouse; however, mice injected with cells with downregulation of Sep15 only had 7.8 +/- 5.4 metastases.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Oncogene. 2009 Aug 20;28(33):2959-68 [19543318.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35540-7 [10945981.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2109-22 [12612082.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Science. 2003 May 30;300(5624):1439-43 [12775843.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2721-7 [12949356.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2907-14 [12949386.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5032-40 [15107826.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Methods Enzymol. 1995;252:199-208 [7476354.001]
  • [Cites] Dis Colon Rectum. 1996 Jun;39(6):628-31 [8646947.001]
  • [Cites] JAMA. 1996 Dec 25;276(24):1957-63 [8971064.001]
  • [Cites] Anal Biochem. 1997 Nov 1;253(1):123-5 [9356150.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5542-8 [15611090.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41568-75 [16230358.001]
  • [Cites] J Nutr. 2006 May;136(5):1311-7 [16614422.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13005-8 [16565519.001]
  • [Cites] IUBMB Life. 2007 Jan;59(1):1-5 [17365173.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4825-32 [17297447.001]
  • [Cites] PLoS One. 2007;2(10):e1112 [17971875.001]
  • [Cites] Eur J Nutr. 2008 Feb;47(1):47-54 [18239845.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6102-9 [11012661.001]
  • (PMID = 20388823.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA080946; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CA / CA080946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Selenoproteins; 0 / Sep15 protein, mouse
  • [Other-IDs] NLM/ NIHMS184300; NLM/ PMC2865577
  •  go-up   go-down


94. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, Lakka S: Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ; 2010 Oct;17(10):1529-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells.
  • Medulloblastoma and neuroblastoma belong to a group of neoplasms designated as primitive neuroectodermal tumors (PNETs).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1998 Dec;54(6):1955-66 [9853260.001]
  • [Cites] FEBS Lett. 1998 Nov 6;438(3):150-8 [9827536.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1124-6 [15326383.001]
  • [Cites] Cell. 2005 Jan 28;120(2):237-48 [15680329.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6802-15 [15557280.001]
  • [Cites] Protein Sci. 2006 Feb;15(2):335-42 [16385004.001]
  • [Cites] Leukemia. 2006 Mar;20(3):426-32 [16424866.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5828-35 [16740722.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):51-64 [16843265.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2161-72 [16886061.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1124-32 [16998475.001]
  • [Cites] Curr Biol. 2007 Jan 9;17(1):1-11 [17208179.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):379-83 [17251378.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):548-58 [16946731.001]
  • [Cites] Autophagy. 2007 Sep-Oct;3(5):452-60 [17534139.001]
  • [Cites] J Biol Chem. 2007 Nov 23;282(47):34457-67 [17897953.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):171-82 [17917680.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1545-52 [17991734.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1069-75 [18305538.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):690-7 [18566436.001]
  • [Cites] Prostate. 2008 Dec 1;68(16):1743-52 [18767033.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5308-16 [19706824.001]
  • [Cites] Mol Cell Neurosci. 1999 Sep;14(3):180-98 [10576889.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5720-8 [11060023.001]
  • [Cites] J Clin Invest. 2000 Nov;106(9):1127-37 [11067865.001]
  • [Cites] Science. 2000 Dec 1;290(5497):1717-21 [11099404.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):21-2 [11134173.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):439-44 [11212227.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):609-22 [11485919.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2045-54 [11733355.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Oct;283(4):G947-56 [12223355.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1035-44 [12437086.001]
  • [Cites] Curr Biol. 2003 Feb 18;13(4):358-63 [12593804.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1809-20 [14638851.001]
  • [Cites] J Biol Chem. 2004 Jan 30;279(5):3578-87 [14581476.001]
  • [Cites] Mol Cancer Res. 2004 Apr;2(4):215-24 [15140943.001]
  • [Cites] J Cell Sci. 2004 Jun 1;117(Pt 13):2805-12 [15169837.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2491-502 [15325587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):1889-92 [6952238.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Immunol. 1994 Nov 1;153(9):4247-55 [7930626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9166-71 [8799172.001]
  • [Cites] Brain Res. 1997 Mar 21;751(2):206-16 [9099807.001]
  • [Cites] Cell. 1998 Aug 21;94(4):481-90 [9727491.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • (PMID = 20339379.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA132853-04; United States / NCI NIH HHS / CA / R01 CA132853-03; United States / NCI NIH HHS / CA / R01 CA132853; United States / NCI NIH HHS / CA / CA132853-04; United States / NCI NIH HHS / CA / CA132853-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 0 / Osteonectin; 0 / RNA, Small Interfering; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3; EC 3.4.22.1 / Cathepsin B
  • [Other-IDs] NLM/ NIHMS263402; NLM/ PMC3025815
  •  go-up   go-down


95. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.
  • Malignant meningiomas are associated with less than 2 years median survival.
  • This report presents an analytical approach to tissue characterization based on matrix-assisted laser desorption ionization time-of-flight (MALDI TOF) mass spectrometry imaging (MSI) which is introduced in an attempt to develop a reference database for predictive classification of brain tumors.
  • A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.